Science · Approach

Targeted probiotics begin with the choice of a specific strain.

We choose each strain according to its properties and the available research. See the strains in our products and the studies linked to them.

Why a specific strain matters

Two strains of the same species can have different properties. When reading a study, we therefore look at the exact strain designation, the dose studied and the group of participants. This information helps to judge what the results apply to.

Species · sameTest 01 / 03Test 02 / 03Test 03 / 03Result

Passage through the digestive tractProduction of metabolitesCooperation with microorganismsSame species · different properties

Strain A

Strain B

SurvivalMetabolitesCooperation Strain A Strain B

PropertiesDifferent

How to read the name on the packaging

Look for the strain designation after the Latin name. Let us show it using an example from iMunobiom+®.

First part of the name

Genus and species

Lacticaseibacillus rhamnosus

The species name covers several strains. It helps place the microorganism in a common group.

Complete designation

And a specific strain

Lacticaseibacillus rhamnosus CRL 1505

CRL 1505 designates a specific strain. Under this code you will find it in scientific publications and in our library below.

What to check when choosing probiotics

When comparing products, look at the composition, dose, research and storage conditions.

Strain designation

The full name of the strain, including the code, lets you trace exactly which microorganisms a product contains.

Amount in the daily dose

CFU is the number of microorganisms that are viable in the dose. Check it through to the end of shelf life, and in studies too.

Scientific sources

Check what was studied, in whom and with what result. For a mixture, also look at its exact composition and dosage.

Storage

Observe the temperature and other conditions on the packaging. They are important for preserving the viability of the microorganisms.

Targeted microbiome modulation: when the strain, the dose and the person all matter

The gut microbiome is not just a list of bacteria. It is a living and constantly changing ecosystem in which microorganisms communicate with each other and with the human body. They take part in processing food components, producing various metabolites and interacting with the intestinal barrier and the immune system. Its composition and activity are influenced by diet, age, environment, medicines taken, health status and many other factors.

That is why there is no single universal “ideal” microbiome composition and no single probiotic suitable for every purpose. When choosing, the question should not be just “How many bacteria does the product contain?” but above all:

Which specific strains does it contain, at what dose were they used and what scientific evidence relates to them?

Targeted microbiome modulation is based precisely on this principle.

What does it mean to modulate the microbiome?

Modulating the microbiome does not mean “resetting” it or simply topping up bacteria that are present in lower amounts in one stool sample. The aim is to deliberately influence selected microbial functions, relationships between microorganisms or their communication with the host.

The tools of such modulation include mainly probiotics and prebiotics. Their effect does not have to be linked to permanent colonisation of the gut or to a marked change in the overall composition of the microbiome. Some microorganisms can act as early as during passage through the digestive tract - for example by producing metabolites, interacting with other members of the microbial ecosystem or communicating with the cells of the intestinal mucosa.

Not every “good bacterium” is a probiotic

The international scientific association ISAPP defines probiotics as:

live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.

This definition contains three essential requirements: the microorganism must be alive, it must be administered in a sufficient amount and its benefit must be scientifically demonstrated. Not every live microorganism, nor every bacterium in a fermented food, therefore automatically meets the criteria of a probiotic (1).

Prebiotics: food for selected microorganisms

Prebiotics are not live microorganisms. According to the ISAPP consensus definition, they are:

substrates that are selectively utilised by host microorganisms and confer a health benefit.

Put simply, prebiotics give selected microorganisms a source they can use for their growth or metabolic activity. Not every fibre is automatically a prebiotic, however. A prebiotic effect must involve selective utilisation by microorganisms and, at the same time, a demonstrated health benefit (2, 3).

Probiotics and prebiotics are thus two different but complementary approaches: a probiotic brings a precisely defined live microorganism, while a prebiotic specifically supports the activity of selected microorganisms.

Why does the exact strain matter?

The name of a probiotic microorganism has several levels. For example, the designation Lacticaseibacillus rhamnosus GG consists of:

Lacticaseibacillus genus,
rhamnosus species,
GG the specific strain.

Strains belonging to the same species may be related, but they do not have to have the same properties or the same clinical effects. They may differ in their ability to survive passage through the digestive tract, produce certain metabolites, communicate with the immune system or cooperate with other microorganisms.

Some basic properties may be shared by several strains of one species. However, the specific result of a clinical study cannot automatically be transferred to all strains of the same species. If a certain benefit was studied for strain GG, it does not mean that every strain of the species L. rhamnosus provides it to the same extent.

A link between a specific microorganism and the scientific evidence is possible only when the strain is precisely identified. That is why a well-described probiotic should state not only the genus and species but also an unambiguous strain designation (4).

Why does the exact dose matter?

The amount is most often expressed in CFU - colony-forming units. A higher number, however, does not automatically mean a better product. A review of human studies showed that the relationship between dose and effect of probiotics is not uniform. For some outcomes monitored, a more pronounced effect of higher doses was observed, for others no clear relationship between dose and outcome was confirmed. The effective dose therefore depends on the specific strain or combination of strains, the purpose of use, the population studied and the method of administration. It cannot be determined by the general rule “the more CFU, the better” alone (5).

Individual strains have been studied in scientific studies at different doses. The amount used in a specific product should therefore correspond to the dose to which the available evidence relates. Likewise, it is not true that a mixture with more strains must be more effective than one or two well-chosen strains.

With multi-strain products it is important to know:

the exact identity of the individual strains,
the amount of the individual strains or the exact composition of the mixture studied,
the dose used in scientific studies,
maintaining a sufficient number of live microorganisms until the end of the shelf life.

A large total CFU figure without information on the representation of individual strains may not be enough to reliably link a product to specific scientific evidence. Expert criteria for probiotics therefore include not only a precisely defined composition but also an adequate number of viable microorganisms at the end of the shelf life and evidence of benefit at the given dose (4).

Targeted and personalised probiotics

The terms targeted probiotics and personalised probiotics are not separate categories in the ISAPP definition. They describe how probiotic strains are selected and combined.

A targeted probiotic contains specific strains chosen for a particular purpose. The selection is based on the properties of the strain, the available clinical or mechanistic evidence, the population studied and the dose used. It is therefore not a random combination of as many microorganisms as possible, but a formulation with clear expert justification.

A personalised probiotic adds to this principle the individual context of a specific person. When choosing the composition, the results of a microbiome analysis can be taken into account together with age, diet, lifestyle, tolerance of individual ingredients and the goal of the intervention.

A microbiome analysis is one layer of information - not a diagnosis on its own and not a simple list of bacteria that need to be “topped up”. Personalisation makes sense when it combines individual data with knowledge about precisely identified strains, their doses, safety and the quality of the available evidence. Tailoring the composition does not in itself guarantee a result; every strain used must still meet the same requirements for precision and expert justification.

The essence of the targeted approach is not as many strains as possible or the highest possible number of billions of CFU. It is the selection of correctly identified microorganisms in justified doses and for a clearly defined purpose.

In the following sections we therefore present individual microorganisms at the level of specific strains - their origin, biological properties, mechanisms studied, available clinical knowledge, doses used and the limits of the current evidence. This makes it possible to distinguish between what has been demonstrated for a specific strain, what has been observed only in laboratory or animal models and what remains the subject of further research.

References and expert sources

Hill, C.,et al. (2014). Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 11(8):506-14. https://pubmed.ncbi.nlm.nih.gov/24912386/
Gibson, G. R., et al. (2017). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol.14(8):491-502. https://pubmed.ncbi.nlm.nih.gov/28611480/
International Scientific Association for Probiotics and Prebiotics (ISAPP), Prebiotics, https://isappscience.org/topic/prebiotics/
Binda, S., et al. (2020). Criteria to Qualify Microorganisms as “Probiotic” in Foods and Dietary Supplements. Frontiers in Microbiology, 11, 1662. https://pmc.ncbi.nlm.nih.gov/articles/PMC7394020/
Ouwehand, A. C. (2017). A review of dose-responses of probiotics in human studies. Beneficial Microbes. ;8(2):143–151.

Strains in our targeted probiotics

Find your product and open the strain profile. There you will find its properties, an overview of the research and links to the studies.

Purpose of the document: The document combines an at-a-glance card, a readable research summary and an expert profile with results tables. For each item, a single numbering of sources applies across all three layers.

How to read the library

Library of microorganisms in the targeted products

18 strains | 7 products | English version 2026

Educational material. A description of research is not automatically an approved health claim or a substitute for diagnosis or treatment.

How the library is organised

Layer 1 – a taxonomic or compositional table and brief points on the areas studied in research.

Layer 2 – an understandable summary of the most important findings with numbered citations.

Layer 3 – tables of clinical and mechanistic results, role in the product, significance of the evidence, safety and scientific sources.

How to read the results: For a precise multi-strain blend, the result belongs to the whole combination. In vitro and animal studies explain a biological mechanism, but do not in themselves demonstrate an effect in humans.

Regulatory note

Specific claims tied to diagnoses or symptoms must pass legal and medical review in the context of the whole page before they are published on a commercial website. The document is an expert content basis, not automatically approved advertising communication.

Short glossary of terms used

The explanations apply to the customer-facing layers of the document. In the titles of publications and in expert tables, the terminology used by the study authors is retained.

Gut microbiome – the community of microorganisms, their genes and the substances they create in the gut environment.

Dysbiosis – a disturbed composition or functioning of the microbiome; it is not a diagnosis in itself.

Metabolites – substances produced by the activity of cells or microorganisms, for example organic acids.

Intestinal barrier and permeability – the intestinal lining regulates the passage of substances; permeability refers to how permeable it is.

Cytokines and IL‑10 – signalling substances of the immune system; IL‑10 is classed among the regulatory cytokines.

Th1, Th2 and Treg – different types of immune response and regulatory T‑cells; it is not a simple “good versus bad” switch.

sIgA – secretory immunoglobulin A, an antibody present mainly on mucous membranes.

GABA, serotonin and AhR – signalling molecules or receptor pathways studied along the gut–brain axis and in communication between the microbiome and the body; a laboratory result cannot be automatically transferred to humans.

Editorial principle for the web: layers 1 and 2 describe identity, composition, biological properties and the direction of scientific research. Layer 3 reproduces the results of specific publications. Neither layer represents a promise of a result, a therapeutic indication or a substitute for healthcare.

HIT na Trávenie+®20 × 10⁹ CFU · digestive comfort

Bifidobacterium animalis subsp. lactis Bi1

Research on the diversity of bifidobacteria in a five-strain blend [1]
Fermentation of selected carbohydrates and production of organic acids
Research on digestive comfort with the exact HIT na Trávenie+® combination [1,2]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Bifidobacterium animalis subsp. lactis Bi1
Older/alternative designation	Bifidobacterium lactis Bi1; B. animalis subsp. lactis Bi1
Classification	domain Bacteria; phylum Actinomycetota; class Actinomycetia; order Bifidobacteriales; family Bifidobacteriaceae
Biological type	Gram-positive, non-spore-forming, predominantly anaerobic bifidobacterium
Availability	part of HIT na Trávenie+®

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Bifidobacterium animalis subsp. lactis Bi1 is the bifidobacterial component of a precisely defined five-strain combination. In the blend it adds to the lactobacilli the ability to ferment selected carbohydrates and produce organic acids, which help shape the gut environment.

In a randomised double-blind study in adults with coeliac disease and persistent IBS‑like complaints, this five-strain blend was associated with improved overall digestive comfort and a favourable change in the representation of bifidobacteria [1]. Laboratory research on the same combination also showed the breakdown of selected gliadin peptides and protection of intestinal barrier markers [2].

Bi1 is one of three bifidobacterial strains in HIT na Trávenie+®. The clinical result belongs to the full combination of Bi1, Bl10, Bbr8, 101/37 and 14D; its individual components were not assessed separately in the study.

Strength and limits of the evidence: The most direct clinical support comes from the precise five-strain blend; the separate contribution of Bi1 was not isolated in the study.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
A precise five-strain blend for persistent IBS‑like complaints in coeliac disease	multicentre, randomised, double-blind, placebo-controlled study; 109 adults with coeliac disease who had IBS‑like symptoms despite a gluten-free diet	IBS‑SSS and GSRS scores fell compared with placebo and response by the study’s criteria was more frequent; the increase in bifidobacteria persisted even after the intervention [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Role in the targeted product

In HIT na Trávenie+®, it complements the two lactobacillus strains with bifidobacterial fermentation and ecological diversity. Clinical claims should be communicated for the combination Bi1 + Bl10 + Bbr8 + 101/37 + 14D, not for Bi1 alone.

Significance of the evidence

The most direct clinical support comes from the precise five-strain blend; the separate contribution of Bi1 was not isolated in the study.

Safety note

Scientific sources

[1] Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms. View source

[2] A Probiotic Preparation Hydrolyzes Gliadin and Protects Intestinal Cells from the Toxicity of Pro-Inflammatory Peptides. View source

Bifidobacterium breve Bl10

Fermentation of oligosaccharides
Research on bifidobacterial diversity
Research on digestive comfort in the clinically studied five-strain blend [1,2]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Bifidobacterium breve Bl10
Older/alternative designation	Bifidobacterium breve Bl10; the documents also use the notation “Bl 10”
Classification	domain Bacteria; phylum Actinomycetota; class Actinomycetia; order Bifidobacteriales; family Bifidobacteriaceae
Biological type	Gram-positive, non-spore-forming anaerobic bifidobacterium
Availability	part of HIT na Trávenie+®

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Bifidobacterium breve Bl10 broadens the bifidobacterial part of the product with a strain of a species that naturally uses various oligosaccharides. Such a fermentation repertoire is of interest for the cooperation between microorganisms in the gut ecosystem.

Bl10 was part of the precise five-strain blend that, in a controlled clinical study, supported an improvement in IBS‑like digestive complaints in adults with coeliac disease [1]. In a cell model the same blend had a favourable effect on selected indicators of the intestinal barrier [2].

In HIT na Trávenie+®, Bl10 works alongside Bi1 and Bbr8. Together they form a diverse bifidobacterial component of the combination, while the clinical evidence applies to the blend as a whole.

Strength and limits of the evidence: The most direct clinical support comes from the precise five-strain blend; the separate contribution of Bl10 was not isolated in the study.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
A precise five-strain blend for persistent IBS‑like complaints in coeliac disease	multicentre, randomised, double-blind, placebo-controlled study; 109 adults with coeliac disease who had IBS‑like symptoms despite a gluten-free diet	IBS‑SSS and GSRS scores fell compared with placebo and response by the study’s criteria was more frequent; the increase in bifidobacteria persisted even after the intervention [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Role in the targeted product

In HIT na Trávenie+®, it broadens the product’s bifidobacterial component and its metabolic complementarity with Bi1 and Bbr8. The effect of the blend cannot be divided between these three strains.

Significance of the evidence

The most direct clinical support comes from the precise five-strain blend; the separate contribution of Bl10 was not isolated in the study.

Safety note

Scientific sources

[1] Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms. View source

[2] A Probiotic Preparation Hydrolyzes Gliadin and Protects Intestinal Cells from the Toxicity of Pro-Inflammatory Peptides. View source

Bifidobacterium breve Bbr8

Strain diversity of the bifidobacterial part of the product
Fermentation role in the gut ecosystem
Research on digestive comfort in the precise five-strain blend [1,2]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Bifidobacterium breve Bbr8
Older/alternative designation	Bifidobacterium breve Bbr8
Classification	domain Bacteria; phylum Actinomycetota; class Actinomycetia; order Bifidobacteriales; family Bifidobacteriaceae
Biological type	Gram-positive, non-spore-forming anaerobic bifidobacterium
Availability	part of HIT na Trávenie+®; also part of the Gut Enricher complex

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Bifidobacterium breve Bbr8 is the second B. breve strain in the five-strain combination. The same species name does not mean the same properties: individual strains can differ in their enzymes, adhesion and in which carbohydrates they can use.

A combination containing Bbr8 produced favourable changes in overall digestive symptom scores in a randomised study [1]. In a laboratory model it also broke down some gliadin peptides and protected selected barrier proteins of intestinal cells [2].

The role of Bbr8 in HIT na Trávenie+® is to broaden strain diversity and metabolic complementarity. The study results belong to the exact five-strain blend, not to Bbr8 alone.

Strength and limits of the evidence: The most direct clinical support comes from the precise five-strain blend; the separate contribution of Bbr8 was not isolated in the study.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
A precise five-strain blend for persistent IBS‑like complaints in coeliac disease	multicentre, randomised, double-blind, placebo-controlled study; 109 adults with coeliac disease who had IBS‑like symptoms despite a gluten-free diet	IBS‑SSS and GSRS scores fell compared with placebo and response by the study’s criteria was more frequent; the increase in bifidobacteria persisted even after the intervention [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Role in the targeted product

In HIT na Trávenie+®, it complements Bl10 and Bi1. Two strains of the same species should not be considered interchangeable; they may differ in enzymes, adhesion and metabolic profile.

Significance of the evidence

The most direct clinical support comes from the precise five-strain blend; the separate contribution of Bbr8 was not isolated in the study.

Safety note

Scientific sources

[1] Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms. View source

[2] A Probiotic Preparation Hydrolyzes Gliadin and Protects Intestinal Cells from the Toxicity of Pro-Inflammatory Peptides. View source

Lacticaseibacillus paracasei 101/37

Production of lactic acid and fermentation metabolites
Completing the lactobacillus part of the combination
Research on digestive comfort and barrier mechanisms in the precise blend [1,2]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Lacticaseibacillus paracasei 101/37
Older/alternative designation	Lactobacillus paracasei 101/37
Classification	domain Bacteria; phylum Bacillota; class Bacilli; order Lactobacillales; family Lactobacillaceae
Biological type	Gram-positive, non-spore-forming lactic acid bacterium
Availability	part of HIT na Trávenie+®

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Lacticaseibacillus paracasei 101/37 is a lactic acid bacterium that brings lactic acid production and other fermentation metabolites to the blend. This complements the bifidobacteria and strain 14D well.

The precise combination with strain 101/37 was clinically studied in adults with coeliac disease and persistent IBS‑like complaints; the assessed digestive scores improved during use [1]. In a cell model the same blend supported the breakdown of selected gliadin peptides and the preservation of intestinal barrier proteins [2].

In HIT na Trávenie+®, 101/37 together with 14D forms the lactobacillus part of the microbial core. Laboratory findings do not mean that the combination replaces a gluten-free diet.

Strength and limits of the evidence: The strain was part of a precise blend studied both clinically and in the laboratory. The results support the combination, not an isolated effect of 101/37.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
A precise five-strain blend for persistent IBS‑like complaints in coeliac disease	multicentre, randomised, double-blind, placebo-controlled study; 109 adults with coeliac disease who had IBS‑like symptoms despite a gluten-free diet	IBS‑SSS and GSRS scores fell compared with placebo and response by the study’s criteria was more frequent; the increase in bifidobacteria persisted even after the intervention [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Role in the targeted product

In HIT na Trávenie+®, it provides a lactobacillus metabolic profile and complements 14D. The result cannot be interpreted as the product’s ability to treat coeliac disease or neutralise gluten.

Significance of the evidence

The strain was part of a precise blend studied both clinically and in the laboratory. The results support the combination, not an isolated effect of 101/37.

Safety note

Scientific sources

[1] Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms. View source

[2] A Probiotic Preparation Hydrolyzes Gliadin and Protects Intestinal Cells from the Toxicity of Pro-Inflammatory Peptides. View source

Lactiplantibacillus plantarum 14D

Metabolic and enzymatic diversity of the blend
Interaction with food peptides studied in vitro [2]
Research on digestive comfort in the precise five-strain combination [1]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Lactiplantibacillus plantarum 14D
Older/alternative designation	Lactobacillus plantarum 14D; in publications also 14D CECT 4528
Classification	domain Bacteria; phylum Bacillota; class Bacilli; order Lactobacillales; family Lactobacillaceae
Biological type	Gram-positive, non-spore-forming, metabolically flexible lactic acid bacterium
Availability	part of HIT na Trávenie+®

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Lactiplantibacillus plantarum 14D is a metabolically flexible strain able to adapt to various food and gut conditions. In the blend it brings a different enzymatic repertoire and complements the fermentation profile of strain 101/37.

A five-strain combination containing 14D was associated with improvement in IBS‑like symptoms in adults with coeliac disease in a randomised clinical study [1]. Mechanistic work on the same blend supported its interaction with gliadin peptides and the intestinal barrier [2].

In HIT na Trávenie+®, 14D is part of the clinically studied microbial core. The results belong to the full combination and do not mean that people with coeliac disease can consume gluten.

Strength and limits of the evidence: The strain was part of a precise blend studied both clinically and in the laboratory. The results support the combination, not an isolated effect of 14D.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
A precise five-strain blend for persistent IBS‑like complaints in coeliac disease	multicentre, randomised, double-blind, placebo-controlled study; 109 adults with coeliac disease who had IBS‑like symptoms despite a gluten-free diet	IBS‑SSS and GSRS scores fell compared with placebo and response by the study’s criteria was more frequent; the increase in bifidobacteria persisted even after the intervention [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Role in the targeted product

In HIT na Trávenie+®, it complements 101/37 with a different set of enzymes and fermentation capabilities. Together with three bifidobacteria, it forms the microbial core of the studied combination.

Significance of the evidence

The strain was part of a precise blend studied both clinically and in the laboratory. The results support the combination, not an isolated effect of 14D.

Safety note

Scientific sources

[1] Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms. View source

[2] A Probiotic Preparation Hydrolyzes Gliadin and Protects Intestinal Cells from the Toxicity of Pro-Inflammatory Peptides. View source

ALLERGIC+®1 × 10⁹ CFU/g · immune balance in the gut

Bifidobacterium bifidum W23

also used in other complexes

Adhesion and laboratory research on the integrity of the intestinal barrier [1]
Mucosal and immunoregulatory mechanisms
Clinical research on seasonal allergic burden in a six-strain blend [2,3]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Bifidobacterium bifidum W23
Older/alternative designation	B. bifidum W23
Classification	domain Bacteria; phylum Actinomycetota; class Actinomycetia; order Bifidobacteriales; family Bifidobacteriaceae
Biological type	Gram-positive, non-spore-forming anaerobic bifidobacterium with a mucosal profile
Availability	part of the product ALLERGIC+®; also used in other complexes

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Bifidobacterium bifidum W23 is a mucosa-oriented strain. Laboratory research showed marked adhesion, interaction with mucin MUC13 and improved integrity of a model intestinal barrier [1].

W23 is part of a six-strain combination studied in seasonal allergic rhinitis. A smaller clinical study recorded an improvement in quality of life and a lower need for rescue medication [2]. Another randomised study of a four-species blend, which also included B. bifidum, produced favourable results in atopic dermatitis in children [4].

In ALLERGIC+® W23 complements the immunoregulatory strains with contact with the mucosa and barrier mechanisms. A larger confirmatory study in seasonal rhinitis did not show a clear difference in the primary outcome [3], so the clinical support for the blend is supportive, not definitive.

Strength and limits of the evidence: Direct barrier research on W23 is complemented by clinical studies of blends. The larger rhinitis study did not confirm a clear primary effect, so the clinical support for the combination is supportive.

Detailed expert profile

Characteristics and biological context

Bifidobacterium bifidum W23 is a mucosa-oriented strain. Laboratory research showed marked adhesion, interaction with mucin MUC13 and improved integrity of a model intestinal barrier [1].

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
W23, MUC13 and the intestinal barrier	controlled in vitro study of several B. bifidum strains; human intestinal epithelial cells	W23 showed high adhesion, sialidase activity and significantly increased barrier integrity [1].	Biological support for a mechanism, which must be distinguished from a clinical effect in humans.
Four-species blend in atopic dermatitis in children	randomised, double-blind, placebo-controlled study; 40 children aged 1 to 13 years	In the intervention group the SCORAD score, selected cytokines and total IgE fell more [4].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Role in the targeted product

In ALLERGIC+® it brings a mucosal and barrier profile. It must not be presented as a strain clinically confirmed on its own against allergy.

Significance of the evidence

Direct barrier research on W23 is complemented by clinical studies of blends. The larger rhinitis study did not confirm a clear primary effect, so the clinical support for the combination is supportive.

Safety note

Scientific sources

[1] Probiotic Bifidobacterium bifidum Strains Desialylate MUC13 and Increase Intestinal Epithelial Barrier Function. View source

[2] A Specifically Designed Multispecies Probiotic Supplement Relieves Seasonal Allergic Rhinitis Symptoms. View source

[3] Assessment of a Multispecies Probiotic Supplement for Relief of Seasonal Allergic Rhinitis. View source

[4] Effect of Probiotics on the Treatment of Children with Atopic Dermatitis. View source

Lactobacillus acidophilus W55

also used in IL‑10 oriented complexes

Research on functional regulatory T cells [1]
IL‑10 oriented immune signalling [1]
Clinical research on seasonal allergic burden in a six-strain blend [2,3]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Lactobacillus acidophilus W55
Older/alternative designation	L. acidophilus W55
Classification	domain Bacteria; phylum Bacillota; class Bacilli; order Lactobacillales; family Lactobacillaceae
Biological type	Gram-positive, non-spore-forming lactic acid bacterium
Availability	part of the product ALLERGIC+®; also used in IL‑10 oriented complexes

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Lactobacillus acidophilus W55 is among the strains studied for the ability to support functional regulatory T‑lymphocytes and IL‑10 oriented immune balance [1]. This is a mechanism by which gut microorganisms communicate with immune cells.

In clinical research, W55 was part of a six-strain blend in seasonal allergic rhinitis; the first study recorded favourable changes in quality of life [2]. Supporting results were also provided by a randomised study of a blend of four of the same bacterial species in atopic dermatitis in children [4].

In ALLERGIC+® W55 brings a regulatory T‑cell and lactobacillus profile. The larger confirmatory rhinitis study had a neutral primary outcome [3], so the clinical findings apply to the combination studied and cannot be attributed to W55 alone.

Strength and limits of the evidence: W55 has a direct mechanistic profile and clinical context from multi-strain blends; the contribution of the strain alone was not separated in the clinical studies.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
Regulatory T cells	in vitro comparative study of lactic acid bacteria on human peripheral blood mononuclear cells (PBMCs)	W55 was among the strains capable of supporting functional regulatory T cells [1].	Biological support for a mechanism, which must be distinguished from a clinical effect in humans.
Four-species blend in atopic dermatitis in children	randomised, double-blind, placebo-controlled study; 40 children aged 1 to 13 years	In the intervention group the SCORAD score, selected cytokines and total IgE fell more [4].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Role in the targeted product

In ALLERGIC+® it brings a Treg/IL‑10 oriented mechanism and a lactobacillus metabolic component.

Significance of the evidence

W55 has a direct mechanistic profile and clinical context from multi-strain blends; the contribution of the strain alone was not separated in the clinical studies.

Safety note

Scientific sources

[1] Lactic Acid Bacteria Differ in Their Ability to Induce Functional Regulatory T Cells in Humans. View source

[2] A Specifically Designed Multispecies Probiotic Supplement Relieves Seasonal Allergic Rhinitis Symptoms. View source

[3] Assessment of a Multispecies Probiotic Supplement for Relief of Seasonal Allergic Rhinitis. View source

[4] Effect of Probiotics on the Treatment of Children with Atopic Dermatitis. View source

Ligilactobacillus salivarius W57

in other portfolio complexes also with a focus on yeasts

Mucosal and fermentative profile
Complementing the species diversity of the combination
Clinical research on allergic rhinitis and atopic dermatitis in blends [1–3]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Ligilactobacillus salivarius W57
Older/alternative designation	Lactobacillus salivarius W57
Classification	domain Bacteria; phylum Bacillota; class Bacilli; order Lactobacillales; family Lactobacillaceae
Biological type	Gram-positive, non-spore-forming lactic acid bacterium
Availability	part of the product ALLERGIC+®; in other portfolio complexes also with a focus on yeasts

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Ligilactobacillus salivarius W57 adds to ALLERGIC+® a species naturally associated with mucosal environments. Its role is to broaden the fermentative and metabolic variety of the combination.

W57 was part of a six-strain blend in which a smaller clinical study recorded an improvement in quality of life in seasonal allergic rhinitis [1]. Supportive clinical context is also provided by a randomised study of a four-species combination containing L. salivarius in atopic dermatitis in children [3].

Research on W57 relies mainly on combinations. A larger confirmatory study in seasonal rhinitis did not show a clear difference in the primary outcome [2], so its contribution is described as a complementary role in the formulation.

Strength and limits of the evidence: The clinical support comes from multi-strain blends. The results support a complementary role of W57 in the formulation.

Detailed expert profile

Characteristics and biological context

Ligilactobacillus salivarius W57 adds to ALLERGIC+® a species naturally associated with mucosal environments. Its role is to broaden the fermentative and metabolic variety of the combination.

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
Six-strain blend in seasonal rhinitis	open-label phase II followed by a randomised double-blind RCT; 40 participants in the first study; 165 randomised in the confirmatory study	In the first clinical study, most participants achieved an improvement in quality of life in seasonal allergic rhinitis [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.
Four-species blend in atopic dermatitis in children	randomised, double-blind, placebo-controlled study; 40 children aged 1 to 13 years	In the intervention group the SCORAD score, selected cytokines and total IgE fell more [3].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Role in the targeted product

In ALLERGIC+® it broadens species and mucosal diversity. Its role is complementary, not clinically confirmed on its own.

Significance of the evidence

The clinical support comes from multi-strain blends. The results support a complementary role of W57 in the formulation.

Safety note

Scientific sources

[1] A Specifically Designed Multispecies Probiotic Supplement Relieves Seasonal Allergic Rhinitis Symptoms. View source

[2] Assessment of a Multispecies Probiotic Supplement for Relief of Seasonal Allergic Rhinitis. View source

[3] Effect of Probiotics on the Treatment of Children with Atopic Dermatitis. View source

Lactococcus lactis W58

also used in Th1/Th2 oriented complexes

Fermentation and lactate production
Immunomodulatory context of multi-strain blends
Early research on eczema in a perinatal three-strain blend [1,2]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Lactococcus lactis W58
Older/alternative designation	L. lactis W58
Classification	domain Bacteria; phylum Bacillota; class Bacilli; order Lactobacillales; family Streptococcaceae
Biological type	Gram-positive, non-spore-forming lactic acid coccus
Availability	part of the product ALLERGIC+®; also used in Th1/Th2 oriented complexes

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Lactococcus lactis W58 brings a different fermentation profile to the combination than lactobacilli and bifidobacteria. It produces lactate and other metabolites that may influence the local microbial environment.

In a perinatal three-strain study with W23 and W52, a lower incidence of eczema was observed at early follow-up in children at high family risk of allergy [1]. W58 was later also included in the six-strain combination studied in seasonal allergic rhinitis; the first open-label study produced a favourable signal [3].

In ALLERGIC+® W58 broadens species and metabolic diversity. Long-term follow-up of the three-strain blend did not confirm prevention of asthma and allergic rhinitis [2] and the larger ALLERGIC+® study had a neutral primary outcome [4]; the most interesting remains the early eczema signal and the role of W58 in combinations.

Strength and limits of the evidence: W58 has clinical context from two different multi-strain blends; the most interesting is the early result of the perinatal eczema study.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
Perinatal three-strain blend and early eczema	randomised, double-blind, placebo-controlled perinatal study with long-term follow-up; children at high family risk of allergy	In early follow-up a lower incidence of eczema was observed in the three-strain group [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.
ALLERGIC+® microbial blend	open-label phase II and confirmatory double-blind RCT; adults with seasonal allergic rhinitis	In the first clinical study, quality of life in seasonal allergic rhinitis improved while taking the six-strain blend [3].	A direct clinical result in the population studied and at the dose used.

Role in the targeted product

In ALLERGIC+® it brings lactococcal fermentative and metabolic distinctiveness and complements the immunomodulatory profile of the other strains.

Significance of the evidence

W58 has clinical context from two different multi-strain blends; the most interesting is the early result of the perinatal eczema study.

Safety note

Scientific sources

[1] The Effects of Selected Probiotic Strains on the Development of Eczema: The PandA Study. View source

[2] Preventive Effects of Selected Probiotic Strains on Asthma and Allergic Rhinitis: The PandA Study. View source

[3] A Specifically Designed Multispecies Probiotic Supplement Relieves Seasonal Allergic Rhinitis Symptoms. View source

[4] Assessment of a Multispecies Probiotic Supplement for Relief of Seasonal Allergic Rhinitis. View source

Bifidobacterium animalis subsp. lactis W51

also used in the Barrier and Bifido Booster complexes

Strain-specific regulation of CD4+ T cells [1,2]
Research on functional regulatory T cells [1]
Bifidobacterial component of ALLERGIC+® [3,4]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Bifidobacterium animalis subsp. lactis W51
Older/alternative designation	Bifidobacterium lactis W51; B. lactis W51
Classification	domain Bacteria; phylum Actinomycetota; class Actinomycetia; order Bifidobacteriales; family Bifidobacteriaceae
Biological type	Gram-positive, non-spore-forming anaerobic bifidobacterium
Availability	part of the product ALLERGIC+®; also used in the Barrier and Bifido Booster complexes

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Bifidobacterium animalis subsp. lactis W51 was studied directly on human immune cells. The results showed a strain-specific cytokine profile and the ability to support functional regulatory T‑lymphocytes [1,2].

W51 is also part of a six-strain combination in seasonal allergic rhinitis. In the first clinical study, most participants improved in quality of life and reduced their need for rescue medication [3].

In ALLERGIC+® W51 combines bifidobacterial fermentation with regulatory immune signalling and complements the mucosa-oriented W23. A larger confirmatory study of the blend did not show a clear difference in the primary outcome [4], so the strongest support for W51 is its direct mechanistic profile.

Strength and limits of the evidence: Direct mechanistic research on W51 is complemented by clinical data from the six-strain blend; the separate clinical contribution of W51 was not determined.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
Regulatory T cells and a strain-specific response	two in vitro comparative studies on human PBMCs and CD4+ T cells	W51 induced its own cytokine profile and supported functional regulatory T cells [1–2].	Biological support for a mechanism, which must be distinguished from a clinical effect in humans.
Six-strain blend in seasonal rhinitis	open-label study followed by a double-blind RCT; 40 and then 165 adults	In the first clinical study, quality of life in seasonal allergic rhinitis improved while taking the six-strain blend [3].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Role in the targeted product

In ALLERGIC+® it combines bifidobacterial fermentation with regulatory immune signalling and complements the mucosa-oriented W23.

Significance of the evidence

Direct mechanistic research on W51 is complemented by clinical data from the six-strain blend; the separate clinical contribution of W51 was not determined.

Safety note

Scientific sources

[1] Lactic Acid Bacteria Differ in Their Ability to Induce Functional Regulatory T Cells in Humans. View source

[2] Gut Derived Lactic Acid Bacteria Induce Strain Specific CD4+ T Cell Responses in Human PBMC. View source

[3] A Specifically Designed Multispecies Probiotic Supplement Relieves Seasonal Allergic Rhinitis Symptoms. View source

[4] Assessment of a Multispecies Probiotic Supplement for Relief of Seasonal Allergic Rhinitis. View source

Lacticaseibacillus casei W56

also used in a Th1/Th2 oriented complex

D‑tryptophan production [1]
Modulation of CCL17/TARC signalling in models [1]
Allergic context in multi-strain blends [2,3]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Lacticaseibacillus casei W56
Older/alternative designation	Lactobacillus casei W56
Classification	domain Bacteria; phylum Bacillota; class Bacilli; order Lactobacillales; family Lactobacillaceae
Biological type	Gram-positive, non-spore-forming lactic acid bacterium
Availability	part of the product ALLERGIC+®; also used in a Th1/Th2 oriented complex

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Lacticaseibacillus casei W56 is notable for its ability to produce D‑tryptophan. In cell and animal models, this metabolite influenced dendritic cells, CCL17/TARC signalling and selected manifestations of allergic inflammation [1].

In the clinical context, W56 was part of a six-strain combination studied in seasonal allergic rhinitis [2]. Another randomised study of a four-species blend containing L. casei recorded favourable changes in atopic dermatitis score and selected immune markers in children [3].

In ALLERGIC+® W56 brings a D‑tryptophan mechanism and complements the regulatory profiles of W23, W55, W51 and W58. Because the clinical studies used blends, the observed results belong to the combinations.

Strength and limits of the evidence: Strain-specific mechanistic research on D‑tryptophan is complemented by clinical studies of blends; the clinical contribution of W56 remains shared with the other components.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
D‑tryptophan and allergic inflammation	cell experiments and an animal model; human cells, dendritic cells and mice	A reduction in CCL17 and easing of selected manifestations of allergic inflammation [1].	Biological support for a mechanism, which must be distinguished from a clinical effect in humans.
ALLERGIC+® microbial blend	randomised, double-blind, placebo-controlled study; 165 adults with seasonal rhinitis	The primary response was similar with the active blend and placebo [2].	A direct clinical result in the population studied and at the dose used.
Four-species blend in atopic dermatitis in children	randomised, double-blind, placebo-controlled study; 40 children aged 1 to 13 years	In the intervention group the SCORAD score, selected cytokines and total IgE fell more [3].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Role in the targeted product

In ALLERGIC+® it brings a D‑tryptophan mechanism and complements the regulatory profiles of W23, W55, W51 and W58.

Significance of the evidence

Strain-specific mechanistic research on D‑tryptophan is complemented by clinical studies of blends; the clinical contribution of W56 remains shared with the other components.

Safety note

Scientific sources

[1] D‑Tryptophan from Probiotic Bacteria Influences the Gut Microbiome and Allergic Airway Disease. View source

[2] Assessment of a Multispecies Probiotic Supplement for Relief of Seasonal Allergic Rhinitis. View source

[3] Effect of Probiotics on the Treatment of Children with Atopic Dermatitis. View source

CARDIObiom+®cardiovascular area

Lactiplantibacillus plantarum ECGC13110402

Research on the lipid profile [1,2]
Research on systolic blood pressure [1]
Cardiometabolic lifestyle

At-a-glance card and understandable research summary

Parameter	Item
Current name	Lactiplantibacillus plantarum ECGC13110402
Older/alternative designation	Lactobacillus plantarum ECGC 13110402; ECGC13110402; LPLDL®
Classification	domain Bacteria; phylum Bacillota; class Bacilli; order Lactobacillales; family Lactobacillaceae
Biological type	Gram-positive, non-spore-forming lactic acid bacterium
Availability	microbial component of the product CARDIObiom+®

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Lactiplantibacillus plantarum ECGC13110402, also known as LPLDL®, was selected for metabolic properties related to cholesterol processing. It is a strain with direct human research on lipid and cardiometabolic markers.

In a twelve-week randomised study, favourable changes in LDL or total cholesterol, triglycerides and systolic pressure were observed in some predefined groups [1]. A follow-up pilot study recorded a decrease in total, LDL and non‑HDL cholesterol and apolipoprotein B [2].

In CARDIObiom+® the strain forms the microbial core, which is complemented by a plant extract, vitamin D3 and thiamine. The research supports its place in the concept of a cardiometabolic lifestyle; the product does not replace treatment prescribed by a doctor.

Strength and limits of the evidence: Two direct human studies support the strain, especially for lipid markers; given the smaller samples, this is an encouraging, developing clinical programme.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
ECGC 13110402 in normal to mild hypercholesterolaemia	randomised, double-blind, placebo-controlled parallel study; 49 adults	Pre-stratified and subsequent subgroup analyses showed a decrease in LDL or total cholesterol, TAG and systolic pressure in some groups; no significant GI safety signal appeared [1].	A direct clinical result in the population studied and at the dose used.
Six-week pilot lipid study	randomised, double-blind, placebo-controlled pilot study; 16 adults with hypercholesterolaemia	In the active group, total, LDL and non‑HDL cholesterol and apolipoprotein B fell compared with placebo [2].	A direct clinical result in the population studied and at the dose used.

Role in the targeted product

In CARDIObiom+® it forms the microbial core with the most direct evidence for lipid markers. The plant extract, vitamin D3 and thiamine complement the formulation, but the finished combination was not tested as a whole in the studies cited.

Significance of the evidence

Two direct human studies support the strain, especially for lipid markers; given the smaller samples, this is an encouraging, developing clinical programme.

Safety note

In healthy people, bifidobacteria and lactic acid bacteria are generally well tolerated; flatulence or a change in stool may appear temporarily at the start. In severe immunodeficiency, critical illness, a central venous catheter or a markedly damaged intestinal barrier, it is advisable to consult a doctor about use. When treating high cholesterol or hypertension, medicine doses must not be changed without a doctor.

Scientific sources

[1] An in vivo assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults. View source

[2] The cholesterol lowering efficacy of Lactobacillus plantarum ECGC 13110402 in hypercholesterolemic adults: A double-blind, randomized, placebo controlled, pilot human intervention study. View source

iMunobiom+®1 × 10⁹ CFU · the body’s defences

Lacticaseibacillus rhamnosus CRL 1505

Mucosal immunity and secretory IgA [1]
Clinical research on respiratory episodes in children [1,2]
Clinical research on the occurrence of recurrent upper respiratory tract infections in adults [3]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Lacticaseibacillus rhamnosus CRL 1505
Older/alternative designation	Lactobacillus rhamnosus CRL1505; Lr1505
Classification	domain Bacteria; phylum Bacillota; class Bacilli; order Lactobacillales; family Lactobacillaceae
Biological type	Gram-positive, non-spore-forming lactic acid bacterium; also described as an immunobiotic strain
Availability	the microbial component of iMunobiom+®

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Lacticaseibacillus rhamnosus CRL 1505 is described as an immunobiotic strain because research on it has long focused on communication between the gut, mucous membranes and the immune system.

In a large double-blind study in children, yogurt with CRL 1505 was associated with fewer infectious episodes, fevers and antibiotics used, and with a favourable mucosal IgA response [1]. Another paediatric RCT supported a combined supplement containing this strain [2]. A new strain-specific study from 2026 recorded a favourable effect on the burden of recurrent upper respiratory tract infections in adults as well [3].

In iMunobiom+®, CRL 1505 is the microbial component, complemented by beta‑glucans and vitamin D. Clinical research on the strain provides a solid scientific foundation, while the outcome of the finished formula depends on its exact composition and dose.

Strength and limits of the evidence: Direct clinical research on CRL 1505 includes children and adults; the individual studies differ in the carrier and composition of the intervention.

Detailed expert profile

Characteristics and biological context

Lacticaseibacillus rhamnosus CRL 1505 is described as an immunobiotic strain because research on it has long focused on communication between the gut, mucous membranes and the immune system.

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
CRL1505 in yogurt with the strain studied	randomised, controlled, double-blind study; 298 healthy children aged 2–5 years in day-care centres	Infectious events occurred in 34 % of children in the intervention group versus 66 % in the control group; there were also fewer fevers and less use of antibiotics [1].	A direct clinical result in the population studied and at the dose used.
Combined immune supplement with CRL1505	randomised, double-blind, placebo-controlled study; 110 children aged 3–10 years completed the study; frequent RTIs in their history	The active combination reduced the number of RTI episodes, days of illness, fevers, cough and runny nose [2].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.
CRL 1505 and respiratory tract resilience in adults	randomised, double-blind, placebo-controlled parallel study; 140 healthy adults randomised, 122 included in the main analysis	The strain reduced the number of participants with at least three episodes by week 16; a lower total number of episodes, a shorter cumulative duration, more infection-free time and lower use of symptomatic medication were recorded [3].	A direct clinical result in the population studied and at the dose used.

Role in the targeted product

In iMunobiom+®, it is the microbial component focused on communication between gut and mucosal immunity. Beta‑glucans and vitamin D are separate active ingredients; their benefits must not be confused with the effect of CRL1505.

Significance of the evidence

Direct clinical research on CRL 1505 includes children and adults; the individual studies differ in the carrier and composition of the intervention.

Safety note

In healthy people, bifidobacteria and lactic acid bacteria are generally well tolerated; flatulence or a change in stool may appear temporarily at the start. In severe immunodeficiency, critical illness, a central venous catheter or a markedly damaged intestinal barrier, it is advisable to consult a doctor about use. In acute high fever, shortness of breath or suspected bacterial infection, a product with microorganisms does not replace examination or treatment.

Scientific sources

[1] Probiotics for Everyone! The Novel Immunobiotic Lactobacillus rhamnosus CRL1505 and the Beginning of Social Probiotic Programs in Argentina. View source

[2] Evaluation of the Effects of an Immune-Boosting Food Supplement on the Severity and Frequency of Pediatric Respiratory Tract Infections. View source

[3] Randomized, Double-Blind, Placebo-Controlled Clinical Trial Assessing the Efficacy of Lacticaseibacillus rhamnosus CRL 1505 in Preventing Upper Respiratory Tract Infections in Healthy Adults. View source

LADYbiom+®10 × 10⁹ CFU · women’s intimate health

Lacticaseibacillus rhamnosus CA15

Research on the vaginal lactobacillus environment [2,3]
Research on bacterial vaginosis and mixed vaginitis [2,3]
Adhesion and inhibition of selected urogenital microorganisms [1]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Lacticaseibacillus rhamnosus CA15
Older/alternative designation	Lactobacillus rhamnosus CA15; DSM 33960
Classification	domain Bacteria; phylum Bacillota; class Bacilli; order Lactobacillales; family Lactobacillaceae
Biological type	Gram-positive, non-spore-forming lactic acid bacterium isolated from the vaginal environment
Availability	the microbial component of LADYbiom+®

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Lacticaseibacillus rhamnosus CA15 (DSM 33960) was isolated from the vaginal environment. In laboratory evaluation, its survival during simulated digestion, adhesion and interaction with selected urogenital microorganisms were monitored [1].

Two randomised double-blind studies examined its oral use. In women with vaginal dysbiosis, bacterial vaginosis or mixed vaginitis, both clinical and microbiological indicators improved after a short intervention and the representation of lactobacilli increased [2,3]. The newer study included 200 women, thereby extending the original pilot observations [3].

In LADYbiom+®, CA15 is the main microbial component targeting the vaginal ecosystem. Saffron and olive extracts and vitamins form complementary parts of the formula.

Strengths and limits of the evidence: Two strain-specific randomised studies provide direct clinical support for CA15; the complete LADYbiom+® product was not tested as a whole in them.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
CA15 in vaginal dysbiosis	randomised, double-blind, placebo-controlled clinical study; 60 women with vaginal dysbiosis	Symptoms, microbiological indicators and lactobacilli abundance improved; the placebo remained largely unchanged [2].	A direct clinical result in the population studied and at the dose used.
Large RCT in bacterial vaginosis and mixed vaginitis	randomised, double-blind, placebo-controlled study; 200 women completed the study	Clinical and microbiological parameters improved after the intervention and at follow-up; the strain was well tolerated [3].	A direct clinical result in the population studied and at the dose used.

Role in the targeted product

In LADYbiom+®, CA15 is the main microbial component targeting the vaginal ecosystem. Saffron and olive extracts and vitamins have their own functional roles; the effects of individual ingredients do not automatically add together.

Significance of the evidence

Two strain-specific randomised studies provide direct clinical support for CA15; the complete LADYbiom+® product was not tested as a whole in them.

Safety note

In healthy people, bifidobacteria and lactic acid bacteria are generally well tolerated; flatulence or a change in stool may appear temporarily at the start. In severe immunodeficiency, critical illness, a central venous catheter or a markedly damaged intestinal barrier, it is advisable to consult a doctor about use. In the case of discharge, pain, bleeding, pregnancy or recurrent complaints, gynaecological diagnosis is necessary; a product with microorganisms does not replace anti-infective treatment.

Scientific sources

[1] Probiotic Characterization of Lacticaseibacillus rhamnosus CA15 (DSM 33960). View source

[2] Lacticaseibacillus rhamnosus CA15 as a New Driver in Restoring the Normal Vaginal Microbiota. View source

[3] Oral Administration of the Probiotic Lacticaseibacillus rhamnosus CA15 in a Large Cohort of Women with Bacterial Vaginosis and Mixed Vaginitis: Clinical Evidence from a Randomized, Double-Blind, Placebo-Controlled Study. View source

SPORTbiom+®5 + 5 × 10⁹ AFU · recovery after exertion

Streptococcus thermophilus FP4

together with BR03

Clinical research on recovery after eccentric exercise in a pair with BR03 [1]
Research on muscle function after intense exertion [1]
Research on the IL‑6 response after exercise [1]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Streptococcus thermophilus FP4
Older/alternative designation	S. thermophilus FP4
Classification	domain Bacteria; phylum Bacillota; class Bacilli; order Lactobacillales; family Streptococcaceae
Biological type	Gram-positive, non-spore-forming thermophilic lactic acid coccus
Availability	microbial component of the product SPORTbiom+® together with BR03

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Streptococcus thermophilus FP4 is a thermophilic lactic acid bacterium that was studied, together with Bifidobacterium breve BR03, in a precise two-strain combination in recovery after intense exercise.

In a randomised crossover study in strength-trained men, after 21 days of taking the pair, less deterioration in isometric strength and range of motion at some time points after eccentric exertion and lower circulating IL‑6 were observed [1].

In SPORTbiom+®, FP4 with BR03 forms the microbial core. The result is directly relevant to this pair, although the study was small and did not separate the individual contributions of FP4 and BR03.

Strength and limits of the evidence: One small randomised crossover study directly supports the pair FP4 + BR03; larger independent studies would refine the size of the effect.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
FP4 + BR03 after muscle-damaging exercise	randomised, double-blind, placebo-controlled crossover study; 15 healthy strength-trained men	The blend eased the decline in isometric torque and range of motion at some time points and reduced circulating IL‑6 within 48 hours [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Role in the targeted product

In SPORTbiom+® it forms, with BR03, a microbial pair aimed at recovery after exertion. The assumed role of FP4 is complementary fermentation and immunometabolic signalling.

Significance of the evidence

One small randomised crossover study directly supports the pair FP4 + BR03; larger independent studies would refine the size of the effect.

Safety note

Scientific sources

[1] Probiotic Streptococcus thermophilus FP4 and Bifidobacterium breve BR03 Supplementation Attenuates Performance and Range-of-Motion Decrements Following Muscle Damaging Exercise. View source

Bifidobacterium breve BR03

together with FP4

Clinical research on recovery after eccentric exercise in a pair with FP4 [1]
Precise genomic identity and traceability [2]
Clinical research in acute diarrhoea in children in another two-strain blend [3]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Bifidobacterium breve BR03
Older/alternative designation	B. breve BR03; DSM 16604
Classification	domain Bacteria; phylum Actinomycetota; class Actinomycetia; order Bifidobacteriales; family Bifidobacteriaceae
Biological type	Gram-positive, non-spore-forming anaerobic bifidobacterium with a publicly published genome
Availability	microbial component of the product SPORTbiom+® together with FP4

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Bifidobacterium breve BR03 (DSM 16604) is a bifidobacterial strain with a publicly published whole-genome sequence, which supports its precise identification and traceability [2].

Together with FP4 it was studied in recovery after muscle-damaging exercise; the two-strain combination had a favourable effect on some indicators of muscle function and inflammatory response after exertion [1]. A new 2026 study examined BR03 in another pair with strain B632 and recorded a shorter duration and lower stool frequency in acute diarrhoea in children [3].

In SPORTbiom+®, BR03 complements FP4 with a bifidobacterial fermentative and immunometabolic component. The paediatric result belongs to the combination BR03 + B632 and does not assess SPORTbiom+®.

Strength and limits of the evidence: BR03 has a public genomic identity and clinical research in two different two-strain combinations; the results apply to the respective blend.

Composition information

HIT na Trávenie+® brings together three bifidobacterial and two lactobacillus strains in the precise combination Bi1, Bl10, Bbr8, 101/37 and 14D. Its advantage is that this microbial core was not put together only in theory, but has been studied as a whole.

In a multicentre randomised study in adults with coeliac disease and persistent IBS‑like complaints, the blend was associated with improved overall digestive scores and a favourable change in bifidobacteria [1]. Laboratory work on the same combination supported the breakdown of selected gliadin peptides and protection of barrier markers [2]. In a large open-label follow-up of adults with IBS, participants often reported improvement in abdominal pain and bloating [3].

Omega‑3 fatty acids and L-lysine add separate nutritional components to the formulation. In coeliac disease the product does not replace a strict gluten-free diet.

Strength and limits of the evidence: The strongest support is a randomised study of the precise five-strain blend; laboratory work and a large open-label follow-up provide additional context.

Composition information

ALLERGIC+® combines two bifidobacterial strains, three lactobacilli and one lactococcus. The formulation brings together barrier, fermentation and immunoregulatory properties, including Treg/IL‑10 signalling and a D‑tryptophan mechanism.

In a smaller clinical study in seasonal allergic rhinitis, quality of life improved and the use of rescue medication decreased while taking the precise six-strain blend [1]. A randomised study of four species corresponding to part of the formulation recorded a favourable change in atopic dermatitis score and selected immune markers in children [3].

A larger confirmatory study in seasonal rhinitis did not show a clear difference in the primary outcome [2]. The overall clinical picture is therefore supportive: it shows interesting potential of the combination, but also the need for more precise selection of the population and further research.

Strength and limits of the evidence: The combination has a positive signal from a smaller study and supporting data from a related four-species blend. The larger confirmatory RCT in seasonal rhinitis had a neutral primary outcome.

Composition information

CARDIObiom+® is built on the strain Lactiplantibacillus plantarum ECGC13110402 (LPLDL®), which has direct human research on the lipid profile. It is complemented by a polyphenol plant extract, vitamin D3 and thiamine.

In a twelve-week randomised study, favourable changes in LDL or total cholesterol, triglycerides and systolic pressure were observed in some groups [1]. A follow-up pilot study supported a decrease in total, LDL and non‑HDL cholesterol and apolipoprotein B [2].

The results support including the strain in a cardiometabolic lifestyle concept. The complete formulation does not replace medical monitoring or prescribed treatment of dyslipidaemia or hypertension.

Strength and limits of the evidence: Strain ECGC13110402 has two direct human studies; the complete formulation with the plant extract and vitamins was not clinically evaluated in this form.

Composition information

iMunobiom+® combines the immunobiotic strain Lacticaseibacillus rhamnosus CRL 1505 with beta‑glucans and vitamin D. The microbial component has a long-term research programme focused on mucosal immunity and respiratory resilience.

In a paediatric double-blind study, yogurt with CRL 1505 was associated with fewer infectious episodes, fevers and antibiotics used [1]. Another study supported a multi-active supplement with this strain in children [2] and a strain-specific RCT from 2026 produced favourable results in recurrent upper respiratory tract infections in adults [3].

Beta-glucans and vitamin D give the strain a separate nutritional and immunological focus. In acute or serious infection the product does not replace diagnosis or treatment.

Strength and limits of the evidence: CRL 1505 has direct clinical research in children and adults. The precise combination with beta-glucans and vitamin D retains its own product context.

Composition information

LADYbiom+® is built around the vaginal strain Lacticaseibacillus rhamnosus CA15 (DSM 33960), selected for its adhesion, resilience and laboratory inhibition of selected urogenital microorganisms [1].

Two randomised double-blind studies examined the oral administration of CA15. In women with vaginal dysbiosis, bacterial vaginosis or mixed vaginitis, clinical and microbiological indicators and the representation of lactobacilli improved [2,3].

The saffron and olive extract and vitamins add further components to the formulation aimed at women’s comfort. In the case of recurrent or marked complaints, gynaecological diagnosis is necessary.

Strength and limits of the evidence: CA15 is supported by two strain-specific RCTs. The studies assessed the strain, not the complete formulation with all plant and vitamin components.

Composition information

SPORTbiom+® combines the precise microbial pair Streptococcus thermophilus FP4 and Bifidobacterium breve BR03 with citrus polyphenols, B vitamins and magnesium.

In a randomised double-blind crossover study in strength-trained men, after 21 days of taking FP4 + BR03, less deterioration in some indicators of muscle function and a lower IL‑6 response after eccentric exercise were observed [1]. BR03 also has a published whole-genome sequence, which supports its precise identity [2].

The study directly supports the microbial pair, although it was a small short-term experiment. Polyphenols and micronutrients broaden the nutritional concept of the product, but were not part of the strain RCT cited.

Strength and limits of the evidence: The precise pair FP4 + BR03 is supported by one small randomised crossover study; the result is promising and suitable for confirmation in a larger sample.

Composition information

VITALbiom+® contains the stable 1:1 Synbio® combination: Lacticaseibacillus rhamnosus IMC 501® and Lacticaseibacillus paracasei IMC 502®. The pair is complemented by pomegranate polyphenols and vitamins B2 and D3.

A double-blind study in healthy adults recorded more frequent and bulkier stools [1]. A meta-analysis of seven studies with 1 095 participants supported a favourable trend in constipation and regularity of bowel movements [2]. Laboratory research described the interaction of both strains with selected bacteria and yeasts [3].

A secondary biomarker analysis of a six-month randomised study in older adults recorded slower shortening of telomeres in leukocytes [4]. This is an interesting biomarker result that complements the main clinical story of the blend, which focuses on digestive comfort and regularity.

Strength and limits of the evidence: The precise Synbio® pair has repeated clinical research and a meta-analysis. Different doses and forms of administration explain part of the variability of the results.

Detailed expert profile

Characteristics and biological context

Bifidobacterium breve BR03 (DSM 16604) is a bifidobacterial strain with a publicly published whole-genome sequence, which supports its precise identification and traceability [2].

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
FP4 + BR03 after muscle-damaging exercise	randomised, double-blind, placebo-controlled crossover study; 15 strength-trained men	The blend eased some functional declines after eccentric exercise and reduced IL‑6 within 48 hours [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.
Genomic identity of BR03	hybrid sequencing and optical mapping; laboratory characterisation of the deposited strain DSM 16604	A genome was assembled on a single scaffold, which strengthens the identity and traceability of the strain [2].	Supports the precise identity and traceability of the strain.
BR03 in a two-strain combination for acute diarrhoea in children	prospective controlled study with alternating allocation; 120 children aged 6 months to 5 years	The two-strain combination was associated with lower stool frequency and a shorter duration of diarrhoea [3].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Role in the targeted product

In SPORTbiom+® it brings a bifidobacterial fermentative and immunomodulatory component that complements FP4.

Significance of the evidence

BR03 has a public genomic identity and clinical research in two different two-strain combinations; the results apply to the respective blend.

Safety note

Scientific sources

[1] Probiotic Streptococcus thermophilus FP4 and Bifidobacterium breve BR03 Supplementation Attenuates Performance and Range-of-Motion Decrements Following Muscle Damaging Exercise. View source

[2] Single-Scaffold Genome Sequence of Probiotic Strain Bifidobacterium breve BR03 (DSM 16604). View source

[3] The beneficial effect of Bifidobacterium breve Br03 and Bifidobacterium breve B632 mixture in acute infectious diarrhea in children. View source

Targeted product 1. HIT na Trávenie+®

Parameter	Item
Microbial composition	B. animalis subsp. lactis Bi1; B. breve Bl10; B. breve Bbr8; L. paracasei 101/37; L. plantarum 14D
Other active ingredients	omega‑3 fatty acids and L-lysine according to the product document
Dose context	product documents state a total of 2 × 10¹⁰ CFU/day; always verify the dose against the current label
Main focus	research focus on digestive comfort and IBS‑like complaints; not a treatment for coeliac disease or a replacement for a gluten-free diet

Properties studied and scientific context

Research on digestive comfort and regularity [1,3]

IBS‑like complaints in clinical research on the precise blend [1]

Barrier and peptide mechanisms studied in vitro [2]

How to read the card: The points describe areas of research on the microbial core or a related formulation. The exact current label and dosage always take precedence.

Composition and role of the individual components

Strain / component	Role in the product concept
B. animalis subsp. lactis Bi1	bifidobacterial fermentation and ecological diversity
B. breve Bl10 + Bbr8	two non-interchangeable strains of the same species with complementary metabolic potential
L. paracasei 101/37	lactobacillus fermentative and acidifying component
L. plantarum 14D	metabolic and enzymatic flexibility

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
A precise five-strain blend for persistent IBS‑like complaints in coeliac disease	multicentre, randomised, double-blind, placebo-controlled study; 109 adults with coeliac disease who had IBS‑like symptoms despite a gluten-free diet	IBS‑SSS and GSRS scores fell compared with placebo and response by the study’s criteria was more frequent; the increase in bifidobacteria persisted even after the intervention [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.
Gliadin peptides and the intestinal barrier	in vitro enzymatic and cell study of the precise five-strain blend; simulated digestion and Caco-2 cells	The blend hydrolysed selected gliadin peptides and eased changes in IL‑6, ROS, ZO‑1 and occludin in a cell model [2].	Biological support for a mechanism, which must be distinguished from a clinical effect in humans.
Real-world follow-up in IBS	prospective open-label uncontrolled study; 1 098 adults with IBS	A large proportion of participants reported improvement in abdominal pain and bloating during the intervention and at follow-up [3].	A direct clinical result in the population studied and at the dose used.

Significance of the evidence

The strongest support is a randomised study of the precise five-strain blend; laboratory work and a large open-label follow-up provide additional context.

Safety note

The product does not replace a gluten-free diet or the diagnosis of coeliac disease. In fish allergy or when taking medicines that affect clotting, the source and dose of omega‑3 on the label must be taken into account.

Scientific sources

[1] Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms. View source

[2] A Probiotic Preparation Hydrolyzes Gliadin and Protects Intestinal Cells from the Toxicity of Pro-Inflammatory Peptides. View source

[3] A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of irritable bowel syndrome in adults. View source

Targeted product 2. ALLERGIC+®

Parameter	Item
Microbial composition	B. bifidum W23; L. acidophilus W55; L. salivarius W57; L. lactis W58; B. animalis subsp. lactis W51; L. casei W56
Other active ingredients	prebiotic fibre and vitamins according to the current label
Dose context	product documents state 2 × 10⁹ CFU/sachet; clinical studies used 4 × 10⁹ CFU/day
Main focus	research focus on seasonal allergic burden and mucosal immunity; not a replacement for antihistamines or allergy treatment

Properties studied and scientific context

Mucosal and regulatory immune signalling [1–3]

Quality of life in seasonal allergic rhinitis [1,2]

Supporting research on atopic dermatitis with a related four-species blend [3]

How to read the card: The points describe areas of research on the microbial core or a related formulation. The exact current label and dosage always take precedence.

Composition and role of the individual components

Strain / component	Role in the product concept
W23	contact with the mucosa and barrier mechanisms
W55 + W51	regulatory T‑cell and cytokine profiles studied in vitro on human immune cells
W56	D‑tryptophan and CCL17 mechanism
W57 + W58	mucosal, fermentative and metabolic diversity

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
Open-label phase II	open-label, baseline-controlled clinical study; 40 adults with seasonal allergic rhinitis	In 25 of 40 participants a clinically meaningful improvement in mRQLQ was achieved and the use of rescue medication decreased [1].	A direct clinical result in the population studied and at the dose used.
Four-species blend in atopic dermatitis in children	randomised, double-blind, placebo-controlled study; 40 children aged 1 to 13 years	In the intervention group the SCORAD score, selected cytokines and total IgE fell more [3].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Significance of the evidence

The combination has a positive signal from a smaller study and supporting data from a related four-species blend. The larger confirmatory RCT in seasonal rhinitis had a neutral primary outcome.

Safety note

In shortness of breath, swelling, anaphylaxis or worsening asthma, immediate medical care is needed. The product does not replace allergy diagnosis or prescribed treatment.

Scientific sources

[1] A Specifically Designed Multispecies Probiotic Supplement Relieves Seasonal Allergic Rhinitis Symptoms. View source

[2] Assessment of a Multispecies Probiotic Supplement for Relief of Seasonal Allergic Rhinitis. View source

[3] Effect of Probiotics on the Treatment of Children with Atopic Dermatitis. View source

Targeted product 3. CARDIObiom+®

Parameter	Item
Microbial composition	Lactiplantibacillus plantarum ECGC 13110402
Other active ingredients	lemon verbena and hibiscus extract, vitamin D3 and thiamine according to the product document
Dose context	the product document states 4 × 10⁹ CFU/day
Main focus	research focus on lipid and cardiometabolic markers in a lifestyle context

Properties studied and scientific context

Clinical research on the lipid profile and apolipoprotein B [1,2]

Clinical research on systolic blood pressure within clinical research on the strain [1]

Cardiometabolic lifestyle

How to read the card: The points describe areas of research on the microbial core or a related formulation. The exact current label and dosage always take precedence.

Composition and role of the individual components

Strain / component	Role in the product concept
ECGC 13110402	direct clinical research on lipid markers
plant extract	a separate polyphenol focus; not part of the strain RCTs
vitamin D3 + thiamine	micronutrient component according to the declared composition

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
ECGC 13110402 in normal to mild hypercholesterolaemia	randomised, double-blind, placebo-controlled parallel study; 49 adults	Pre-stratified and subsequent subgroup analyses showed a decrease in LDL or total cholesterol, TAG and systolic pressure in some groups; no significant GI safety signal appeared [1].	A direct clinical result in the population studied and at the dose used.
Six-week pilot lipid study	randomised, double-blind, placebo-controlled pilot study; 16 adults with hypercholesterolaemia	In the active group, total, LDL and non‑HDL cholesterol and apolipoprotein B fell compared with placebo [2].	A direct clinical result in the population studied and at the dose used.

Significance of the evidence

Strain ECGC13110402 has two direct human studies; the complete formulation with the plant extract and vitamins was not clinically evaluated in this form.

Safety note

In diagnosed dyslipidaemia, hypertension or cardiovascular disease, medical monitoring is the foundation. Prescribed treatment must not be changed on the basis of the results of a small supplementary study.

Scientific sources

[1] An in vivo assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults. View source

Targeted product 4. iMunobiom+®

Parameter	Item
Microbial composition	Lacticaseibacillus rhamnosus CRL1505
Other active ingredients	beta-glucans and vitamin D according to the product document
Dose context	verify the precise dose of the strain and beta-glucans against the current label
Main focus	research focus on mucosal immune indicators and respiratory episodes

Properties studied and scientific context

Mucosal IgA response [1]

Clinical research on respiratory episodes in children [1,2]

Clinical research on the occurrence of recurrent upper respiratory tract infections in adults [3]

How to read the card: The points describe areas of research on the microbial core or a related formulation. The exact current label and dosage always take precedence.

Composition and role of the individual components

Strain / component	Role in the product concept
CRL1505	mucosal immunomodulation and clinical research on infectious episodes
beta-glucans	a separate component with innate immune signalling
vitamin D	vitamin components with authorised claims only when the conditions of their use are met

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
CRL1505 in yogurt with the strain studied	randomised, controlled, double-blind study; 298 healthy children aged 2–5 years in day-care centres	Infectious events occurred in 34 % of children in the intervention group versus 66 % in the control group; there were also fewer fevers and less use of antibiotics [1].	A direct clinical result in the population studied and at the dose used.
Combined immune supplement with CRL1505	randomised, double-blind, placebo-controlled study; 110 children aged 3–10 years completed the study; frequent RTIs in their history	The active combination reduced the number of RTI episodes, days of illness, fevers, cough and runny nose [2].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.
CRL 1505 and respiratory tract resilience in adults	randomised, double-blind, placebo-controlled parallel study; 140 healthy adults randomised, 122 included in the main analysis	The strain reduced the number of participants with at least three episodes by week 16; a lower total number of episodes, a shorter cumulative duration, more infection-free time and lower use of symptomatic medication were recorded [3].	A direct clinical result in the population studied and at the dose used.

Significance of the evidence

CRL 1505 has direct clinical research in children and adults. The precise combination with beta-glucans and vitamin D retains its own product context.

Safety note

The product is a supplement, not prevention or treatment of a serious infection. In high fever, difficulty breathing, dehydration or a worsening condition, examination is necessary.

Scientific sources

[1] Probiotics for Everyone! The Novel Immunobiotic Lactobacillus rhamnosus CRL1505 and the Beginning of Social Probiotic Programs in Argentina. View source

[2] Evaluation of the Effects of an Immune-Boosting Food Supplement on the Severity and Frequency of Pediatric Respiratory Tract Infections. View source

Targeted product 5. LADYbiom+®

Parameter	Item
Microbial composition	Lacticaseibacillus rhamnosus CA15 (DSM 33960)
Other active ingredients	saffron and olive leaf extracts and vitamins according to the product document
Dose context	the CA15 clinical studies used 10¹⁰ CFU/day for 10 days; verify the commercial dose on the label
Main focus	research focus on the vaginal microbiome and subjective comfort in those prone to dysbiosis

Properties studied and scientific context

Research on the vaginal lactobacillus environment [2,3]

Clinical research on bacterial vaginosis and mixed vaginitis in CA15 research [2,3]

Adhesion and inhibition of selected urogenital microorganisms [1]

How to read the card: The points describe areas of research on the microbial core or a related formulation. The exact current label and dosage always take precedence.

Composition and role of the individual components

Strain / component	Role in the product concept
CA15	main microbial component with direct clinical data
saffron and olive extract	a separate plant-based focus; its contribution cannot be inferred from the CA15 RCT
vitamins	supplementary micronutrient component according to the label

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
CA15 in vaginal dysbiosis	randomised, double-blind, placebo-controlled clinical study; 60 women with vaginal dysbiosis	Symptoms, microbiological indicators and lactobacilli abundance improved; the placebo remained largely unchanged [2].	A direct clinical result in the population studied and at the dose used.
Large RCT in bacterial vaginosis and mixed vaginitis	randomised, double-blind, placebo-controlled study; 200 women completed the study	Clinical and microbiological parameters improved after the intervention and at follow-up; the strain was well tolerated [3].	A direct clinical result in the population studied and at the dose used.

Significance of the evidence

CA15 is supported by two strain-specific RCTs. The studies assessed the strain, not the complete formulation with all plant and vitamin components.

Safety note

In pain, fever, bleeding, foul-smelling discharge, pregnancy or recurrent episodes, gynaecological diagnosis is necessary. A product with microorganisms does not replace antibiotic or antifungal treatment.

Scientific sources

[1] Probiotic Characterization of Lacticaseibacillus rhamnosus CA15 (DSM 33960). View source

[2] Lacticaseibacillus rhamnosus CA15 as a New Driver in Restoring the Normal Vaginal Microbiota. View source

Targeted product 6. SPORTbiom+®

Parameter	Item
Microbial composition	Streptococcus thermophilus FP4 + Bifidobacterium breve BR03
Other active ingredients	micronised citrus polyphenols, B vitamins and magnesium according to the product document
Dose context	the study of the microbial pair used 5 × 10⁹ cells of each strain/day; verify the current product dose on the label
Main focus	research focus on recovery after intense muscular exertion and a composition designed for a sports context

Properties studied and scientific context

Clinical research on recovery after intense muscle exertion [1]

Clinical research on muscle function and range of motion after eccentric exercise [1]

Clinical research on the IL‑6 response after exertion [1]

How to read the card: The points describe areas of research on the microbial core or a related formulation. The exact current label and dosage always take precedence.

Composition and role of the individual components

Strain / component	Role in the product concept
FP4	fermentative and immunometabolic component
BR03	bifidobacterial component with a published genome
citrus polyphenols + micronutrients	additional nutritional focus outside the strain RCT

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
FP4 + BR03 after muscle-damaging exercise	randomised, double-blind, placebo-controlled crossover study; 15 healthy strength-trained men	The blend eased the decline in isometric torque and range of motion at some time points and reduced circulating IL‑6 within 48 hours [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.

Significance of the evidence

The precise pair FP4 + BR03 is supported by one small randomised crossover study; the result is promising and suitable for confirmation in a larger sample.

Safety note

The product does not replace adequate recovery, hydration and professional examination of an injury. In severe pain, swelling, dark urine or suspected rhabdomyolysis, urgent medical care is needed.

Scientific sources

[1] Probiotic Streptococcus thermophilus FP4 and Bifidobacterium breve BR03 Supplementation Attenuates Performance and Range-of-Motion Decrements Following Muscle Damaging Exercise. View source

[2] Single-Scaffold Genome Sequence of Probiotic Strain Bifidobacterium breve BR03 (DSM 16604). View source

Targeted product 7. VITALbiom+®

Parameter	Item
Microbial composition	Lacticaseibacillus rhamnosus IMC 501® + Lacticaseibacillus paracasei IMC 502® in a 1:1 ratio (Synbio®)
Other active ingredients	pomegranate/polyphenols and vitamins B2 and D3 according to the product document
Dose context	verify the dose of Synbio® and the declared CFU concentration against the current label
Main focus	research focus on digestive comfort, regularity and selected markers in older age

Properties studied and scientific context

Research on regularity of bowel movements [1,2]

Clinical research on constipation and digestive comfort in the Synbio® clinical programme [1,2]

Biomarker of telomere stability in older adults [4]

How to read the card: The points describe areas of research on the microbial core or a related formulation. The exact current label and dosage always take precedence.

Composition and role of the individual components

Strain / component	Role in the product concept
IMC 501®	adhesion, fermentation and antimicrobial component
IMC 502®	complementary fermentation, coaggregation and metabolic stability
polyphenols + vitamins	additional components that were not part of all Synbio® studies

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
Synbio® and bowel habits	double-blind, placebo-controlled nutritional study; 50 healthy adults	Stool frequency and volume and faecal lactobacilli and bifidobacteria increased [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.
Synbio® meta-analysis in constipation	systematic review and meta-analysis of 7 randomised controlled trials; 1 095 mostly healthy adults	Overall, the constipation score and regularity of bowel movements improved [2].	A direct clinical result in the population studied and at the dose used.
Synbio® and a cellular biomarker of healthy ageing	secondary biomarker analysis of samples from a six-month randomised, double-blind, placebo-controlled study; 46 adults aged 60 years and over	In the group taking Synbio®, slower shortening of telomeres in leukocytes was observed [4].	An interesting clinical biomarker result; it does not constitute evidence of a specific health outcome.

Significance of the evidence

The precise Synbio® pair has repeated clinical research and a meta-analysis. Different doses and forms of administration explain part of the variability of the results.

Safety note

In long-standing or newly developed constipation, blood in the stool, weight loss or severe abdominal pain, examination is necessary. A product with microorganisms does not replace diagnosis of the cause of the complaints.

Scientific sources

[1] Influence of a combination of two potential probiotic strains, Lactobacillus rhamnosus IMC 501® and Lactobacillus paracasei IMC 502® on bowel habits of healthy adults. View source

[2] Probiotic SYNBIO® Blend’s Impact on Constipation in Healthy Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. View source

[3] In vitro evaluation of antimicrobial activity of Lactobacillus rhamnosus IMC 501®, Lactobacillus paracasei IMC 502® and SYNBIO® against pathogens. View source

[4] Probiotic Supplementation in Aged Human Subjects Counteracts Leukocyte Telomere Attrition Rate. View source

Methodology and general notice

The starting point was seven scientific product PDFs supplied by the client: ALLERGIC+®, CARDIObiom+®, HIT na Trávenie+®, iMunobiom+®, LADYbiom+®, SPORTbiom+® and VITALbiom+®. These sources were reconciled with primary publications and supplemented with studies attributable to specific strains or blends available up to August 2026.

Taxonomic names reflect the modern reclassification of lactobacilli; historical designations remain in the tables for easy comparison with older articles and labels. The Latin name of a microorganism is written in italics; the strain designation remains upright.

Before publication: The final web text should go through regulatory, legal and medical review. For products, current labels, specifications, certificates of analysis, allergen data and approved conditions of use take precedence.

General sources

[G1] Reclassification of the Genus Lactobacillus into 25 Genera. View source

[G2] Expert Consensus Document: The Scope and Appropriate Use of the Term Probiotic. View source

[G3] World Gastroenterology Organisation Global Guideline: Probiotics and Prebiotics. View source

VITALbiom+®2.5 + 2.5 × 10⁹ CFU · healthy ageing

Lacticaseibacillus rhamnosus IMC 501®

as part of the 1:1 blend Synbio® with IMC 502®

Research on regularity of bowel movements in the Synbio® blend [1,2]
Research on digestive comfort and bloating in the clinical programme of the blend [1,2]
Laboratory interaction with selected bacteria and yeasts [3]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Lacticaseibacillus rhamnosus IMC 501®
Older/alternative designation	Lactobacillus rhamnosus IMC 501®; DSM 16104
Classification	domain Bacteria; phylum Bacillota; class Bacilli; order Lactobacillales; family Lactobacillaceae
Biological type	Gram-positive, non-spore-forming lactic acid bacterium isolated from a healthy older person
Availability	in VITALbiom+® as part of the 1:1 Synbio® blend with IMC 502®

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Lacticaseibacillus rhamnosus IMC 501® was isolated from a healthy older person and is most often used clinically in the fixed pair Synbio® with IMC 502®. The strains were selected to complement each other in fermentation, adhesion and interaction with selected microorganisms [3].

In a double-blind study, stool frequency and volume increased after taking the precise pair [1]. A meta-analysis of seven clinical studies with 1 095 participants supported a favourable trend in constipation and regularity of bowel movements [2]. A secondary biomarker analysis of a six-month randomised study in older adults recorded slower shortening of telomeres in leukocytes, which is an interesting biomarker result [4].

In VITALbiom+®, IMC 501® forms half of the Synbio® blend. The clinical results belong to the IMC 501® + IMC 502® pair, which was administered as a single combination in the studies.

Strength and limits of the evidence: The strongest support is for the precise Synbio® pair. The studies repeatedly assessed IMC 501® and IMC 502® together.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
Synbio® and bowel habits	double-blind, placebo-controlled nutritional study; 50 healthy adults	Stool frequency and volume and faecal lactobacilli and bifidobacteria increased [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.
Synbio® meta-analysis in constipation	systematic review and meta-analysis of 7 randomised controlled trials; 1 095 mostly healthy adults	Overall, the constipation score and regularity of bowel movements improved [2].	A direct clinical result in the population studied and at the dose used.
Synbio® and a cellular biomarker of healthy ageing	secondary biomarker analysis of samples from a six-month randomised, double-blind, placebo-controlled study; 46 adults aged 60 years and over	In the group taking Synbio®, slower shortening of telomeres in leukocytes was observed [4].	An interesting clinical biomarker result; it does not constitute evidence of a specific health outcome.

Role in the targeted product

In VITALbiom+®, it forms half of the Synbio® blend. It provides an adhesive, fermentative and antimicrobial component; pomegranate polyphenols and vitamins were not studied in the same finished combination in the cited studies.

Significance of the evidence

The strongest support is for the precise Synbio® pair. The studies repeatedly assessed IMC 501® and IMC 502® together.

Safety note

Scientific sources

[1] Influence of a combination of two potential probiotic strains, Lactobacillus rhamnosus IMC 501® and Lactobacillus paracasei IMC 502® on bowel habits of healthy adults. View source

[2] Probiotic SYNBIO® Blend’s Impact on Constipation in Healthy Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. View source

[3] In vitro evaluation of antimicrobial activity of Lactobacillus rhamnosus IMC 501®, Lactobacillus paracasei IMC 502® and SYNBIO® against pathogens. View source

[4] Probiotic Supplementation in Aged Human Subjects Counteracts Leukocyte Telomere Attrition Rate. View source

Lacticaseibacillus paracasei IMC 502®

as part of the 1:1 blend Synbio® with IMC 501®

Research on regularity of bowel movements in the Synbio® blend [1,2]
Complementary fermentation and adhesion [3]
Research on digestive comfort in the precise two-strain combination [1,2]

At-a-glance card and understandable research summary

Parameter	Item
Current name	Lacticaseibacillus paracasei IMC 502®
Older/alternative designation	Lactobacillus paracasei IMC 502®; DSM 16105
Classification	domain Bacteria; phylum Bacillota; class Bacilli; order Lactobacillales; family Lactobacillaceae
Biological type	Gram-positive, non-spore-forming lactic acid bacterium isolated from a healthy older person
Availability	in VITALbiom+® as part of the 1:1 Synbio® blend with IMC 501®

How to read the card: The points describe areas in which the strain or the precise blend was studied. They do not imply a guaranteed result or a substitute for treatment.

Information about the microorganism

Lacticaseibacillus paracasei IMC 502® is the other half of the stable 1:1 combination Synbio®. It complements IMC 501® with a different fermentative and adhesive repertoire, and its interaction with selected bacteria and yeasts was studied under laboratory conditions [3].

Synbio® clinical studies focus mainly on regularity of bowel movements and digestive comfort. A double-blind study recorded more frequent and bulkier stools [1] and a meta-analysis of seven studies supported a favourable overall trend in constipation [2]. A secondary biomarker analysis of a six-month randomised study in older adults also recorded a favourable change in a biomarker of telomere stability [4].

In VITALbiom+®, IMC 502® is used together with IMC 501®. The research therefore best supports the exact Synbio® pair, rather than one strain in isolation.

Strength and limits of the evidence: The strongest support is for the precise Synbio® pair. The studies repeatedly assessed IMC 501® and IMC 502® together.

Detailed expert profile

Characteristics and biological context

Overview of scientific studies

Area studied	Type of research	What the studies showed	Significance of the result
Synbio® and bowel habits	double-blind, placebo-controlled nutritional study; 50 healthy adults	The blend increased stool frequency and volume and influenced selected groups of gut bacteria [1].	The result supports the combination studied; the contribution of the individual strain was not assessed separately.
Synbio® meta-analysis in constipation	systematic review and meta-analysis of 7 randomised controlled trials; 1 095 participants	A pooled analysis supported an improvement in constipation and regularity [2].	A direct clinical result in the population studied and at the dose used.
Synbio® and a cellular biomarker of healthy ageing	secondary biomarker analysis of samples from a six-month randomised, double-blind, placebo-controlled study; 46 adults aged 60 years and over	In the group taking Synbio®, slower shortening of telomeres in leukocytes was observed [4].	An interesting clinical biomarker result; it does not constitute evidence of a specific health outcome.

Role in the targeted product

In VITALbiom+®, it complements IMC 501® with fermentation, adhesion and antimicrobial diversity. Clinical claims belong to the Synbio® blend.

Significance of the evidence

The strongest support is for the precise Synbio® pair. The studies repeatedly assessed IMC 501® and IMC 502® together.

Safety note

Scientific sources

[1] Influence of a combination of two potential probiotic strains, Lactobacillus rhamnosus IMC 501® and Lactobacillus paracasei IMC 502® on bowel habits of healthy adults. View source

[2] Probiotic SYNBIO® Blend’s Impact on Constipation in Healthy Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. View source

[3] In vitro evaluation of antimicrobial activity of Lactobacillus rhamnosus IMC 501®, Lactobacillus paracasei IMC 502® and SYNBIO® against pathogens. View source

[4] Probiotic Supplementation in Aged Human Subjects Counteracts Leukocyte Telomere Attrition Rate. View source

The profiles present what is known about individual strains in the context of the research cited. When comparing with a product, take into account the composition studied and the dose. We give genus names according to the current taxonomy; in older literature and on older packaging you will find some strains under the original genus Lactobacillus.

Prebiotic and bioactive ingredients

Explore the other ingredients in our formulations as well. In the profiles you will find their characteristics, studied properties and scientific sources.

What the document offers: a single overview of prebiotics, fibre ingredients, plant extracts, fatty acids, amino acids, vitamins, minerals and technological substances – with a clear distinction between a research result and the function in the formulation.

How to read the library

Library of additional ingredients in blends with microorganisms

Personalised and targeted products • Slovak version 2026

Compiled from product documentation, a working spreadsheet and verified expert sources available up to August 2026. The document does not replace the label, the certificate of analysis or a legal assessment of health claims.

How to use the library

The library brings together substances from personalised blocks and from targeted products. The same ingredient is handled only once, and the profile lists all the products in which it was identified in the supplied documentation.

Parameter	Item
Layer 1	overview card: identity, category, origin, products and main role
Layer 2	clear customer summary: why the ingredient is of interest and what is important to know
Layer 3	expert profile: the most important studies, design, dose, result, limits of the evidence and sources
Numbering	citations [1], [2]… start again from the beginning for each substance so that they do not break when chapters are moved

An important distinction: “Prebiotic” is not a general name for every bulking agent or fibre. A substance must be selectively utilised by host microorganisms and bring a health benefit. Ordinary maltodextrin, digestible starch, lactose, microcrystalline cellulose, L-glutamine or zinc L-methionine are therefore not automatically labelled as prebiotics in this library.

Short glossary of terms used

The explanations apply to the customer-facing layers of the document. In the titles of publications and in expert tables, the terminology used by the study authors is retained.

Prebiotic ingredient – a substance selectively utilised by microorganisms for which a health benefit has been demonstrated; not every fibre or bulking agent is a prebiotic.

Dietary fibre – an indigestible or partly digestible component of food; its effect depends on structure, dose and fermentability.

Polyphenols – plant bioactive compounds that can also be converted by the action of the gut microbiome.

Metabolites and SCFAs – substances produced by metabolism; SCFAs are short-chain fatty acids, for example acetate, propionate and butyrate.

Intestinal permeability – the permeability of the intestinal lining, which in research is assessed by various laboratory methods.

Oxidative stress – a state of imbalance between the production of reactive molecules and antioxidant defence mechanisms.

Authorised EFSA/EU claim – the claim may be used only in the approved wording and where the conditions on the amount of the nutrient in the specific product are met.

Ingredient map — overview

Ingredient	Category	Product / use	Status
GOS	prebiotic oligosaccharide	POWERbiom+®	confirmed in the product documentation
Whole golden kiwifruit extract	plant fibre and polyphenol component	POWERbiom+®	confirmed
Hesperidin + naringin	citrus flavobiotic	Mikrobióm+®, Flavonoidy+	400 mg + 25 mg in the daily dose according to the documentation
EPA + DHA from microalgae	omega-3 fatty acids	iProbio omega-3; HIT na Trávenie+®	Omega-3 150 mg EPA + 100 mg DHA/capsule; HIT EPA 136 mg, DHA 72 mg
β-(1,3)-(1,6)-D-glucan	structural polysaccharide	iMunobiom+®	confirmed
Lemon verbena + hibiscus	polyphenol extract	CARDIObiom+®	confirmed
Pomegranate / punicalagins	polyphenol extract	VITALbiom+®	confirmed
Saffron	plant extract	LADYbiom+®	confirmed
Olive leaves	plant extract	LADYbiom+®	confirmed
Micronised citrus polyphenols	plant extract	SPORTbiom+®	confirmed
Green tea / EGCG	catechin extract	block with pasteurised A. muciniphila Mucᵀ	Confirmed, 38 mg of green tea extract per 1 g of blend, i.e. 38–76 mg of extract a day at a dose of 1–2 g. The exact EGCG content is not stated in the available documentation and must be verified in the current CoA or raw material specification.
2′-FL	HMO / oligosaccharide studied as a prebiotic	personalised formulations	optional ingredient according to the working list
Inulin and oligofructose	prebiotic fibre	personalised formulations	optional ingredient
Psyllium	gel-forming fibre	personalised formulations	optional ingredient
Acacia fibre	soluble fermentable fibre	personalised formulations	optional ingredient
PHGG	soluble fermentable fibre	personalised formulations	optional ingredient
Konjac glucomannan	viscous soluble fibre	personalised formulations	optional ingredient
Resistant potato starch	resistant starch	personalised formulations	only where the certificate confirms the resistant fraction
Pea fibre	dietary fibre	personalised formulations	optional ingredient
L-glutamine	amino acid	personalised formulations	optional ingredient; not a prebiotic
NAC	amino acid derivative	personalised formulations	optional ingredient; not a prebiotic
L-lysine	essential amino acid	HIT na Trávenie+®	confirmed
Zinc L-methionine	mineral-amino acid complex	personalised formulations	optional ingredient; not a prebiotic

Galacto-oligosaccharides (GOS)

PREBIOTIC OLIGOSACCHARIDES

Research on the abundance of bifidobacteria
research on regularity and digestive comfort
research on microbial and metabolic markers

At-a-glance card and understandable research summary

Parameter	Item
Name	Galacto-oligosaccharides (GOS)
Category	prebiotic oligosaccharides
Origin / nature	short chains of galactose; produced industrially from lactose using β-galactosidase
Products / formulations	POWERbiom+®; potentially other formulas only according to the current label
Main role	substrate selectively utilised by gut microorganisms

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

GOS are among the best-studied prebiotic oligosaccharides. They pass through the upper digestive tract largely undigested and are used in the large intestine by selected microorganisms. It is precisely the selective use by microorganisms of the gut microbiome that distinguishes a prebiotic from an ordinary indigestible bulking agent [1].

In POWERbiom+®, GOS are combined with whole golden kiwifruit extract. However, the clinical results for GOS relate to specific doses in grams; they cannot automatically be applied to another dose or to the full combination without checking the label.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Digestive comfort and microbiome [2]	blinded randomised placebo-controlled study; 44 adults with IBS	3.5 or 7 g/day, 12 weeks	GOS increased faecal bifidobacteria; at the lower dose, several of the digestive symptoms assessed improved.	Small study and a specific trans-GOS; the effect depends on dose and baseline status.
Metabolic and immune markers [3]	double-blind randomised crossover study; 45 adults with overweight and risk features of metabolic syndrome	5.5 g/day, two 12-week periods	An increase in bifidobacteria and favourable changes in selected faecal, inflammatory and metabolic markers were observed.	The results belong to the dose and ingredient tested; they are not evidence of the effect of the finished POWERbiom+® product.

Strength and limits of the evidence

Clinical research on specific GOS raw materials is available, but the effects depend on structure, purity and dose.

Safety note

Gas or bloating may appear at the start. With marked sensitivity to fermentable carbohydrates, it is advisable to increase the dose gradually. GOS may be made from lactose; residual lactose and allergen data should be verified in the specification.

Scientific sources

[1] Gibson GR et al. The ISAPP consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017. View source

[2] Silk DBA et al. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in IBS. Aliment Pharmacol Ther. 2009. View source

[3] Vulevic J et al. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the faecal microbiota and immune function of overweight adults. J Nutr. 2013. View source

Whole golden kiwifruit extract

PLANT FIBRE AND POLYPHENOL COMPONENT

research on regularity of bowel movements
research on the composition of the gut microbiome
plant fibre and polyphenols

At-a-glance card and understandable research summary

Parameter	Item
Name	Whole golden kiwifruit extract
Category	plant fibre and polyphenol component
Origin / nature	whole fruits of Actinidia chinensis; contain soluble and insoluble fibre, polyphenols and natural enzymes
Products / formulations	POWERbiom+®
Main role	complements GOS with a complex plant matrix

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Whole golden kiwifruit extract is not a single isolated molecule. It is a food matrix combining fibre, polyphenols and other natural components of the fruit. In POWERbiom+®, it partners with GOS.

Small randomised studies with encapsulated kiwifruit powder examined mainly the gut microbiota and regularity. The changes observed are interesting, but the response was individual and the results must not be confused with the effect of fresh kiwifruit or of every kiwifruit extract [1].

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Microbiome in functional constipation [1]	randomised crossover study; 20 healthy and 9 functionally constipated participants	golden kiwifruit 2 400 mg/day; 4 weeks per intervention	In a small subgroup with functional constipation, the abundance of Faecalibacterium prausnitzii increased.	A very small subgroup; a microbial marker, not a universal clinical result.
Microbiome and digestive comfort [2]	randomised double-blind placebo-controlled study; 85 healthy adults	standardised golden kiwifruit powder 600 mg/day, 28 days	An increase in Faecalibacterium prausnitzii and a decrease in bloating and in selected microbial groups associated with hydrogen production were observed.	The results belong to the exact ingredient and dose studied; the study was short and did not assess the finished POWERbiom+® product.

Strength and limits of the evidence

Clinical data exist, but they are based on small samples and specific standardised kiwifruit powders.

Safety note

Kiwi is among the known food allergens. Caution is needed in kiwi allergy or latex-fruit syndrome. With a higher fibre intake, gas may temporarily increase.

Scientific sources

[1] Blatchford P et al. Consumption of kiwifruit capsules increases Faecalibacterium prausnitzii abundance in functionally constipated individuals: a randomised controlled human trial. J Nutr Sci. 2017. View source

[2] McKeen S et al. Livaux® gold kiwifruit powder consumption at 600 mg per day for 28 days increases Faecalibacterium prausnitzii numbers and decreases bloating and hydrogenotrophic species numbers in healthy individuals, consistent with slow fermentation: a randomized controlled trial. Bioact Carbohydr Diet Fibre. 2025. View source

2′-Fucosyllactose (2′-FL)

HUMAN MILK OLIGOSACCHARIDE (HMO); INGREDIENT STUDIED AS A PREBIOTIC

Research on the abundance of selected bifidobacteria
research on tolerance and microbiome composition
HMO ingredient with a precisely defined structure

At-a-glance card and understandable research summary

Parameter	Item
Name	2′-Fucosyllactose (2′-FL)
Category	human milk oligosaccharide (HMO); ingredient studied as a prebiotic
Origin / nature	oligosaccharide structurally identical to the naturally occurring 2′-FL in human milk
Products / formulations	optional ingredient of personalised formulations according to the working list
Main role	substrate usable by selected gut microorganisms

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

2′-FL is one of the most abundant oligosaccharides in human milk. Supplements use a microbially produced, purified ingredient of defined identity. EFSA assessed it as a novel food under specified conditions of use [1].

In a clinical study in healthy adults, 2′-FL on its own and in combination with another HMO was well tolerated and changed the abundance of some bacterial groups [2]. This does not mean that every dose of 2′-FL will have the same effect in every population.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Tolerance and microbiome [2]	randomised double-blind placebo-controlled study; healthy adults	various doses of 2′-FL or 2′-FL + LNnT; 2 weeks	The supplements were generally well tolerated and shifted the microbiota towards a higher abundance of bifidobacteria in some participants.	Short duration; combinations of HMOs and several doses were also studied.
Safety assessment [1]	EFSA scientific assessment	conditions of use according to the authorisation	EFSA concluded that the proposed uses and intake levels are safe.	A safety opinion is not evidence of a health effect.

Strength and limits of the evidence

Good support for the identity and safety of authorised raw materials; clinical research on effects in adults is still developing.

Safety note

Only an authorised raw material in the permitted category and dose should be used. For products for children, pregnant or breastfeeding people, the age and population conditions of the current authorisation must be checked.

Scientific sources

[1] EFSA NDA Panel. Safety of 2′-O-fucosyllactose as a novel food ingredient pursuant to Regulation (EC) No 258/97. EFSA Journal. 2015. View source

[2] Elison E et al. Oral supplementation of healthy adults with 2′-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota. Br J Nutr. 2016. View source

Inulin and oligofructose-enriched inulin

INULIN FRUCTANS; FERMENTABLE PREBIOTIC FIBRE

Research on the abundance of bifidobacteria
research on stool regularity
production of microbial metabolites

At-a-glance card and understandable research summary

Parameter	Item
Name	Inulin and oligofructose-enriched inulin
Category	inulin fructans; fermentable prebiotic fibre
Origin / nature	most often chicory root; a mixture of fructan chains of different lengths
Products / formulations	optional personalised formulations; inulin P7 per the working list
Main role	fermentable substrate for the microbiota and fibre component

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Inulin and oligofructose are among the classic prebiotics. Different chain length affects the rate of fermentation, tolerance and the place in the large intestine where the fibre is used [1].

Clinical studies show mainly changes in bifidobacteria and, at a suitable dose, support for regularity. Oligofructose-enriched inulin is not automatically more effective for everyone; what matters in practice is the total dose and gradual titration.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Regularity in adults [2]	randomised controlled study; 97 adults with low fibre intake and irregular stools	oligofructose 5–15 g/day, 4 weeks per dose	At 15 g/day, stool frequency increased; digestive sensations remained low overall.	The result concerns a specific oligofructose and a relatively high dose.
Newer metabolic research [3]	double-blind RCT; 42 adults with MASLD	oligofructose-enriched inulin 16 g/day, 24 weeks	The share of bifidobacteria increased; the main marker of liver fat did not change compared with placebo.	A positive microbial signal, but not evidence of a universal clinical effect.

Strength and limits of the evidence

Strong support for prebiotic character; clinical significance depends on dose and goal.

Safety note

Dose-dependent fermentation effects are common – gas, bloating or softer stool. With sensitivity to fructans/FODMAPs, start low.

Scientific sources

[1] Gibson GR et al. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology. 1995. View source

[2] Buddington RK et al. Oligofructose Provides Laxation for Irregularity Associated with Low Fiber Intake. Nutrients. 2017. View source

[3] Mayengbam S et al. Effects of combined prebiotic fiber supplementation and weight loss counseling in adults with MASLD: a randomized controlled trial. Eur J Nutr. 2025. View source

Psyllium

GEL-FORMING SOLUBLE FIBRE

Research on regularity and stool consistency
research on LDL cholesterol
fibre with a predominantly physical, not merely fermentative, action

At-a-glance card and understandable research summary

Parameter	Item
Name	Psyllium
Category	gel-forming soluble fibre
Origin / nature	seed husks of Plantago ovata
Products / formulations	optional ingredient of personalised formulations according to the working list
Main role	binds water and changes the physical properties of the intestinal contents

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

On contact with water, psyllium forms a gel that binds water and changes the physical properties of the intestinal contents. This is a well-described property of fibre; the result in a specific product depends mainly on the dose and sufficient fluid intake.

Its effects are not based solely on supporting the microbiota. Clinical research is extensive, especially for regularity and lipid parameters [1–2].

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
LDL cholesterol [1]	systematic review and meta-analysis of controlled studies	doses varied between studies	Psyllium reduced LDL and other atherogenic lipid markers.	The effect is tied to regular intake and a sufficient dose of fibre.
Long-term use [2]	multicentre randomised double-blind study; people with hypercholesterolaemia	5.1 g twice a day, 26 weeks	Compared with placebo, total and LDL cholesterol decreased.	The study was an addition to a dietary regimen; it is not a substitute for treatment.

Strength and limits of the evidence

Good clinical support for the physiological effects of fibre; prebiotic fermentation is secondary and variable.

Safety note

Take with enough fluid. Not suitable with swallowing difficulties or suspected narrowing of the digestive tract. May slow the absorption of medicines, so a time interval is advisable, as stated in the medicine’s package leaflet.

Scientific sources

[1] Jovanovski E et al. Effect of psyllium fiber on LDL cholesterol and alternative lipid targets: a systematic review and meta-analysis. Am J Clin Nutr. 2018. View source

[2] Anderson JW et al. Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy. Am J Clin Nutr. 2000. View source

Acacia fibre (gum arabic)

SOLUBLE FERMENTABLE FIBRE

dietary fibre studied as a prebiotic
Research on the abundance of bifidobacteria and lactobacilli
good technological solubility

At-a-glance card and understandable research summary

Parameter	Item
Name	Acacia fibre (gum arabic)
Category	soluble fermentable fibre
Origin / nature	purified acacia exudate, most often Senegalia senegal and related species
Products / formulations	optional ingredient of personalised formulations according to the working list
Main role	gently fermentable fibre and technological binder

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Acacia fibre dissolves well and ferments more slowly than some short-chain fructans. In practice it is therefore of interest where a fibre with a milder onset of fermentation is sought.

In a controlled study in healthy adults, at gram doses it increased bifidobacteria and lactobacilli [1]. This result relates to standardised gum arabic, not to every technological gum used in trace amounts.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Prebiotic effect [1]	randomised controlled study; healthy adults	various doses, 4 weeks	At a suitable dose, bifidobacteria and lactobacilli increased; a dose of around 10 g/day was judged optimal in the study.	The doses are substantially higher than ordinary technological amounts in a capsule.
Tolerance of blends [2]	controlled intervention study	FOS or a blend of FOS + acacia gum	The blend was studied for fermentation and gut comfort.	The result belongs to the combination, not to acacia fibre on its own.

Strength and limits of the evidence

Clinical support for prebiotic action at gram doses.

Safety note

Possible gas, especially with a rapid increase in dose. Caution is advisable in allergy to acacia gums or marked sensitivity to fermentable fibres.

Scientific sources

[1] Calame W et al. Gum arabic establishes prebiotic functionality in healthy human volunteers in a dose-dependent manner. Br J Nutr. 2008. View source

[2] Goetze O et al. Effect of a prebiotic mixture on intestinal comfort and general wellbeing in health. Br J Nutr. 2008. View source

Partially hydrolysed guar gum (PHGG)

SOLUBLE, LOW-VISCOSITY FERMENTABLE FIBRE

digestive comfort
regularity
fermentation and microbial metabolites

At-a-glance card and understandable research summary

Parameter	Item
Name	Partially hydrolysed guar gum (PHGG)
Category	soluble, low-viscosity fermentable fibre
Origin / nature	enzymatically shortened galactomannan from guar plant seeds
Products / formulations	optional ingredient of personalised formulations according to the working list
Main role	fibre studied as a prebiotic with good miscibility

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

PHGG retains the fibre character of guar gum, but thanks to partial hydrolysis it has a lower viscosity and is easier to dose into drinks or powder blends.

Clinical studies examined mainly IBS symptoms and regularity. Results are favourable for some symptoms, but not consistent for every population [1–2].

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Bloating in IBS [1]	randomised double-blind placebo-controlled study	PHGG, 12 weeks	Bloating decreased in particular; not all the symptoms monitored changed.	The result cannot be extended to all forms of IBS.
PHGG versus wheat bran [2]	randomised study; adults with IBS	fibre intervention	PHGG was better tolerated and improved symptom ratings in some patients.	Older study; different protocols and rating scales.

Strength and limits of the evidence

Clinical support for selected digestive symptoms; dose and tolerance are decisive.

Safety note

Start with a lower dose and increase gradually. Possible gas or a change in stool. In acute abdominal pain of unclear origin, fibre should not be started without an examination.

Scientific sources

[1] Russo L et al. Partially hydrolyzed guar gum in the treatment of irritable bowel syndrome with constipation: effects of gender, age, and BMI. Saudi J Gastroenterol. 2015. View source

[2] Parisi GC et al. High-fiber diet supplementation in patients with irritable bowel syndrome: a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum. Dig Dis Sci. 2002. View source

Konjac glucomannan

HIGH-VISCOSITY SOLUBLE FIBRE

regularity
feeling of fullness
authorised EU claims only when the exact dose conditions are met

At-a-glance card and understandable research summary

Parameter	Item
Name	Konjac glucomannan
Category	high-viscosity soluble fibre
Origin / nature	tuber of Amorphophallus konjac
Products / formulations	optional ingredient of personalised formulations according to the working list
Main role	binds a large amount of water and increases the viscosity of the digesta

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Glucomannan is a highly hydrophilic fibre. Its practical effect depends on sufficient water and on spreading the dose through the day.

Where the exact conditions are met, the EU permits claims on the maintenance of normal blood cholesterol levels and on contributing to weight loss in the context of an energy-restricted diet [1]. These claims cannot be used if the product does not reach the set daily dose.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Constipation [2]	randomised double-blind study; adults with constipation	konjac glucomannan, 4 weeks	Bowel movement frequency increased and some markers of the gut environment changed.	Small sample; the effect depends on hydration and dose.
Regulatory assessment [1]	authorised list of EU health claims	cholesterol: 4 g/day; weight: 3 g/day in three doses before meals with water	Claims are permitted only when the exact conditions of use are met.	This is not a universal recommendation for every consumer.

Strength and limits of the evidence

A well-characterised fibre; for communication, the conditions of the authorised claims are decisive.

Safety note

Always take with enough water. Not suitable with swallowing difficulties or a narrowed digestive tract. May affect the absorption of medicines; a time interval is advisable.

Scientific sources

[1] Commission Regulation (EU) No 432/2012 – consolidated list of permitted health claims. View source

[2] Chen HL et al. Supplementation of konjac glucomannan into a low-fiber Chinese diet promoted bowel movement and improved colonic ecology in constipated adults. J Am Coll Nutr. 2008. View source

Resistant potato starch

FERMENTABLE RESISTANT STARCH

production of short-chain fatty acids
individual microbiota responses
important distinction from ordinary potato starch

At-a-glance card and understandable research summary

Parameter	Item
Name	Resistant potato starch
Category	fermentable resistant starch
Origin / nature	starch fraction resistant to digestion in the small intestine
Products / formulations	optional personalised ingredient only where the specification confirms resistant starch
Main role	substrate for fermentation in the large intestine

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Resistant starch is not a synonym for ordinary potato starch. Only the fraction that resists digestion and reaches the large intestine is of interest as a prebiotic.

In human intervention studies, resistant potato starch often increased bifidobacteria and, in some people, butyrate. The response, however, depended strongly on the presence of microorganisms able to break down starch [1–2].

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Butyrate and microbiome [1]	intervention study; 174 healthy young adults	resistant potato starch, 2 weeks	Of the fibre interventions studied, it produced the largest average increase in SCFAs, including butyrate.	Responses were highly individual and depended on the baseline microbiota.
Personalised response [2]	intervention study; 20 healthy adults	resistant starch	The butyrate-production response was related to which microorganisms were present before the intervention.	Supports personalisation, not a guaranteed effect.

Strength and limits of the evidence

Good biological support; clinical response is heterogeneous.

Safety note

Possible gas and bloating. The documentation must state the type and content of the resistant starch; without this the raw material should not be labelled a prebiotic.

Scientific sources

[1] Baxter NT et al. Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers. mBio. 2019. View source

[2] Venkataraman A et al. Variable responses of human microbiomes to dietary supplementation with resistant starch. Microbiome. 2016. View source

Pea fibre

DIETARY FIBRE WITH SOLUBLE AND INSOLUBLE FRACTIONS

regularity
stool volume
dietary fibre; not automatically a selective prebiotic

At-a-glance card and understandable research summary

Parameter	Item
Name	Pea fibre
Category	dietary fibre with soluble and insoluble fractions
Origin / nature	pea seeds or hulls Pisum sativum
Products / formulations	optional ingredient of personalised formulations according to the working list
Main role	increase in total fibre intake and stool volume

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Pea fibre is a practical source of dietary fibre. Depending on how it is processed, it may contain a different proportion of soluble and insoluble fractions, so individual raw materials may behave differently.

Clinical data mainly support an effect on stool volume and frequency [1]. The label “prebiotic” is appropriate only if the specific raw material meets the criterion of selective utilisation by microorganisms of the gut microbiome and there are data to show it.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Stool frequency [1]	controlled intervention study; seniors in a long-term care facility	lightly processed pea fibre in foods	Adding pea fibre increased stool frequency.	The result relates to a specific form and population; it is not microbiome-selective evidence.

Strength and limits of the evidence

Expert support for the role of dietary fibre; prebiotic status must be assessed for the specific raw material.

Safety note

Increase the dose gradually and drink enough fluids. In legume allergy, verify the origin and residual protein content.

Scientific sources

[1] Dahl WJ et al. Increased stool frequency occurs when finely processed pea hull fiber is added to usual foods consumed by elderly residents in long-term care. J Am Diet Assoc. 2003. View source

β-(1,3)-(1,6)-D-glucan

STRUCTURAL POLYSACCHARIDE FROM THE YEAST CELL WALL

research on the innate immune response
research on the course of common respiratory episodes
different from oat β-(1,3)-(1,4)-glucan

At-a-glance card and understandable research summary

Parameter	Item
Name	β-(1,3)-(1,6)-D-glucan
Category	structural polysaccharide from the yeast cell wall
Origin / nature	most often Saccharomyces cerevisiae; the effect depends on purity and structure
Products / formulations	iMunobiom+®
Main role	separate immunologically studied component of the combination

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Yeast β-glucan is an insoluble structural component of the yeast cell wall. Its biological properties depend on the β-(1,3)/(1,6) linkages, molecular weight, branching and purity – results for one raw material therefore cannot automatically be transferred to all β-glucans.

In iMunobiom+®, it complements the bacterial strain and vitamin D. Clinical studies with specific yeast β-glucans mainly investigated the number or severity of common respiratory episodes [1–2].

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Recurrent colds [1]	multicentre double-blind randomised placebo-controlled study; 162 healthy adults with recurrent infections	900 mg/day, 16 weeks	In the per-protocol analysis, the number of symptomatic episodes was lower and some accompanying ratings were better.	The result belongs to the specific yeast raw material; ITT and PP analyses may differ.
Symptom severity [2]	double-blind randomised placebo-controlled study; healthy adults	standardised yeast β-glucan	During the first week of a respiratory episode, some physical symptoms were milder.	Not all markers and time periods were affected equally.

Strength and limits of the evidence

Clinical studies exist, but they are specific to the raw material.

Safety note

Usually well tolerated; possible gas or digestive discomfort. In autoimmune disease or immunosuppressive treatment, consultation with a doctor is advisable.

Scientific sources

[1] Auinger A et al. Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body’s defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study. Eur J Nutr. 2013. View source

[2] Dharsono T et al. Effects of Yeast (1,3)-(1,6)-Beta-Glucan on Severity of Upper Respiratory Tract Infections. J Am Coll Nutr. 2019. View source

Citrus flavobiotic: hesperidin + naringin

STANDARDISED CITRUS POLYPHENOL EXTRACT; FLAVOBIOTIC

research on SCFAs and the butyrate profile
research on microbiome composition
consumer data on digestive comfort

At-a-glance card and understandable research summary

Parameter	Item
Name	Citrus flavobiotic: hesperidin + naringin
Category	standardised citrus polyphenol extract; flavobiotic
Origin / nature	unripe fruits of Citrus sinensis and Citrus paradisi
Products / formulations	Mikrobióm+®; Flavonoidy+
Main role	polyphenols metabolised by the gut microbiome; not a classic fermentable fibre

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Mikrobióm+® and Flavonoidy+ contain the same targeted citrus pair: hesperidin and naringin. The documentation lists 400 mg of hesperidin and 25 mg of naringin in 500 mg of extract per daily dose. In the large intestine, flavonoids are also converted into hesperetin and naringenin and, in the process, communicate in both directions with microorganisms of the gut microbiome [1].

A double-blind RCT with 500 mg of extract a day showed a favourable shift in the ratio of short-chain fatty acids towards butyrate and changes in selected bacterial groups [2]. The decrease in calprotectin was only a trend and should not be presented as a confirmed anti-inflammatory effect.

Mikrobióm+® was also monitored for three months in an internal consumer survey (97 questionnaires sent out, 56 complete responses) that assessed users’ overall satisfaction with the product. Because the survey had no placebo, no blinding and no control group and is based solely on the self-assessment of existing users, it is indicative feedback from real-world use of the product – not clinical evidence of an effect on health. These data should not be used as a basis for a health claim.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Gut metabolites [2]	12-week randomised double-blind placebo-controlled study; 50 adults with overweight	500 mg/day	The share of butyrate in total SCFAs and the butyrate-to-acetate ratio increased; selected microbial groups changed.	Small sample; metabolic and microbial markers, not a therapeutic outcome.
Human colon model [3]	validated in vitro TIM-2 model with microorganisms of the gut microbiome from healthy donors	250 and 350 mg, 72 hours	An increase in SCFAs and changes in the composition of the microbiota were observed.	A laboratory model cannot be directly converted into an effect in humans.
Consumer experience [4]	uncontrolled prospective consumer study; 97 questionnaires, 56 complete participants	500 mg/day; 3 months	Participants completed a questionnaire on overall satisfaction with the product after 3 months of use; the individual areas assessed are not published as separate health outcomes.	No placebo, no blinding, self-assessment and selection of product users.

Strength and limits of the evidence

One published small RCT on gut metabolic responses, in vitro support and our own uncontrolled consumer study.

Safety note

Citrus flavonoids were well tolerated in the studies cited. Naringin and grapefruit components may affect the metabolism of some medicines; for medicines carrying a grapefruit warning, use should be discussed with a doctor.

Scientific sources

[1] Stevens Y et al. The Intestinal Fate of Citrus Flavanones and Their Effects on Gastrointestinal Health. Nutrients. 2019. View source

[2] Sost MM et al. Citrus Extract High in Flavonoids Beneficially Alters Intestinal Metabolic Responses in Subjects with Features of Metabolic Syndrome. Foods. 2023. View source

[3] Sost MM et al. A Citrus Fruit Extract High in Polyphenols Beneficially Modulates the Gut Microbiota of Healthy Human Volunteers in a Validated In Vitro Model of the Colon. Nutrients. 2021. View source

[4] Perbiotix. Mikrobióm+® – three-month consumer study; internal/product document, 2026.

Polyphenol extract of lemon verbena and hibiscus

STANDARDISED PLANT POLYPHENOL COMBINATION

research on blood pressure
research on appetite and body composition
research on polyphenol metabolites and the microbiota

At-a-glance card and understandable research summary

Parameter	Item
Name	Polyphenol extract of lemon verbena and hibiscus
Category	standardised plant polyphenol combination
Origin / nature	Lippia citriodora + Hibiscus sabdariffa; verbascoside and anthocyanins
Products / formulations	CARDIObiom+®
Main role	plant bioactive ingredient alongside the bacterial strain, vitamin D3 and thiamine

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

This combination brings together the polyphenols of lemon verbena and hibiscus. Standardisation is important because the clinical study results belong to the exact extract, not to ordinary tea or any mixture of the two plants.

Randomised studies examined blood pressure, body composition and appetite regulation [1–3]. In CARDIObiom+® the extract is part of a multi-active formulation; the effects of individual ingredients do not add up automatically.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Blood pressure [1]	double-blind randomised placebo-controlled study; 80 adults with prehypertension or stage 1 hypertension	standardised HS–LC extract; 84 days	Mainly daytime systolic blood pressure decreased; diastolic pressure showed no clear change.	One centre and one specific ingredient; this is not evidence of the effect of the complete CARDIObiom+® product.
Appetite [2]	8-week randomised double-blind crossover study; 33 adults with overweight/obesity	standardised extract	Favourable changes were observed in the feeling of fullness, spontaneous food intake and selected appetite hormones.	Small sample; subjective and metabolic markers.
Body composition [3]	randomised double-blind placebo-controlled study	standardised combination, 8 weeks	Favourable changes in body weight and fat mass were recorded.	The result cannot be transferred to non-standardised extracts.

Strength and limits of the evidence

Several RCTs with the exact polyphenol extract; the finished CARDIObiom+® as a whole was not tested in these studies.

Safety note

With antihypertensive medicines or a tendency to low blood pressure, it is advisable to monitor blood pressure. Plant extracts may interact with medicines; in pregnancy and in liver disease, professional consultation is advisable.

Scientific sources

[1] Marhuenda J et al. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of a polyphenolic extract for reducing blood pressure. Molecules. 2021. View source

[2] Serna A et al. Effectiveness of a polyphenolic extract on appetite regulation in overweight and obese grade I population. Eur J Nutr. 2022. View source

[3] Herranz-López M et al. Differential effects of a combination of Hibiscus sabdariffa and Lippia citriodora polyphenols in overweight/obese subjects. Sci Rep. 2019. View source

Pomegranate extract

POLYPHENOL EXTRACT STANDARDISED TO ELLAGITANNINS/PUNICALAGINS

metabolism of ellagitannins
microbiota-dependent urolithin formation
research on antioxidant and cellular markers

At-a-glance card and understandable research summary

Parameter	Item
Name	Pomegranate extract
Category	polyphenol extract standardised to ellagitannins/punicalagins
Origin / nature	Punica granatum
Products / formulations	VITALbiom+®
Main role	source of polyphenols that the gut microbiome converts into urolithins

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

After ingestion, pomegranate punicalagins are converted into ellagic acid and then, via the gut microbiome, into urolithins. The ability to form urolithin A differs between people – a good example of how the microbiome influences the use of a plant ingredient.

Human pharmacokinetic studies confirm the formation of metabolites after ingestion of a standardised extract [1–2]. Clinical results for urolithin A on its own cannot automatically be attributed to pomegranate extract, because each person produces a different amount of urolithins.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Absorption and metabolism [1]	open-label intervention study; healthy volunteers	single dose of a standardised extract	Ellagitannin metabolites were identified in blood and urine; short-term plasma antioxidant capacity increased.	Acute pharmacokinetics, not a long-term clinical effect.
Punicalagin and urolithins [2]	clinical pharmacokinetic study	250 or 1 000 mg of extract; 48-hour follow-up	The conversion of punicalagin to ellagic acid and the later appearance of microbiota-derived urolithins were confirmed.	Metabolites and their amounts differ between people.

Strength and limits of the evidence

A good basis for metabolism and bioactivation by microorganisms of the gut microbiome; clinical benefits depend on the specific extract and the person’s metabolic type.

Safety note

Usually well tolerated. With anticoagulant treatment, several medicines or an allergy to pomegranate, consultation is advisable. Standardisation and checks for contaminants are important.

Scientific sources

[1] Mertens-Talcott SU et al. Absorption, metabolism, and antioxidant effects of pomegranate polyphenols after ingestion of a standardised extract. J Agric Food Chem. 2006. View source

[2] Wang YH et al. Development of an LC–MS/MS method for characterizing pomegranate extract pharmacokinetics in humans. J Pharm Biomed Anal. 2023. View source

Saffron extract

STANDARDISED PLANT EXTRACT

research on premenstrual symptoms
research on mood
a separate ingredient in the LADYbiom+® combination

At-a-glance card and understandable research summary

Parameter	Item
Name	Saffron extract
Category	standardised plant extract
Origin / nature	stigmas of Crocus sativus; bioactive components vary with standardisation
Products / formulations	LADYbiom+®
Main role	plant ingredient aimed at women’s comfort and mental well-being

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Saffron is a botanical raw material for which purity and standardisation are especially important. Clinical studies examined specific extracts and doses, most often in the area of mood and premenstrual symptoms.

In a randomised double-blind study, 30 mg of saffron daily reduced the overall PMS score compared with placebo [1]. The result belongs to saffron alone; LADYbiom+® also contains a bacterial strain, olive extract and vitamins.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Premenstrual comfort [1]	double-blind randomised placebo-controlled study; 50 women aged 20–45	30 mg/day for two menstrual cycles	Compared with placebo, the total score of premenstrual symptoms and depressive symptoms decreased.	Small study and short duration; the effect is tied to the specific extract and population.

Strength and limits of the evidence

Clinical support exists for specific saffron extracts; the complete LADYbiom+® product was not investigated in this study.

Safety note

Do not use in pregnancy without a doctor’s approval. Caution with medicines affecting mood, blood pressure or blood clotting. Verify the authenticity and standardisation of the raw material.

Scientific sources

[1] Agha-Hosseini M et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG. 2008. View source

Olive leaf extract

POLYPHENOL PLANT EXTRACT

research on lipid markers
research on bone turnover
standardisation to oleuropein/polyphenols

At-a-glance card and understandable research summary

Parameter	Item
Name	Olive leaf extract
Category	polyphenol plant extract
Origin / nature	leaves of Olea europaea; typically oleuropein and hydroxytyrosol derivatives
Products / formulations	LADYbiom+®
Main role	separate polyphenol component of the formulation

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Olive leaves contain a different polyphenol matrix from olive oil. When interpreting research, it is therefore important to look at the source, the dose and the oleuropein content.

A twelve-month double-blind study in postmenopausal women with reduced bone mass recorded favourable changes in osteocalcin and lipid profile with 250 mg of extract daily [1]. The result does not demonstrate the effect of the complete LADYbiom+® blend.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Bone turnover and lipids [1]	12-month randomised double-blind controlled study; 64 postmenopausal women with osteopenia	250 mg extract + 1 g calcium/day	Osteocalcin increased and some lipid markers improved compared with the calcium control group.	The extract was given together with calcium; the result relates to the specific standardisation.

Strength and limits of the evidence

One longer RCT with a specific extract and further emerging clinical research.

Safety note

May strengthen the effect of medicines for blood pressure or glucose. Caution with anticoagulants and in pregnancy. Checking for residues and standardisation is important.

Scientific sources

[1] Filip R et al. Twelve-month consumption of a polyphenol extract from olive in a double blind, randomized trial increases serum total osteocalcin levels and improves serum lipid profiles in postmenopausal women with osteopenia. J Nutr Health Aging. 2015. View source

Micronised citrus polyphenols from sweet orange

PLANT POLYPHENOL EXTRACT FOR A SPORTS FORMULATION

research on performance during intense exercise
research on oxidative stress
micronisation aimed at the physical properties of the raw material

At-a-glance card and understandable research summary

Parameter	Item
Name	Micronised citrus polyphenols from sweet orange
Category	plant polyphenol extract for a sports formulation
Origin / nature	Citrus sinensis; composition depends on the specific standardised raw material
Products / formulations	SPORTbiom+®
Main role	polyphenol component alongside the microbial strains studied, B vitamins and magnesium

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Micronisation reduces the particle size of the extract and may improve its dispersion. On its own, however, it is not evidence of better biological efficacy; the exact raw material and dose are what matter.

In smaller sports RCTs, citrus polyphenol extracts were associated with a slight improvement in some performance markers [1–2]. These results concern the extracts tested and cannot be attributed to the whole SPORTbiom+® formulation without a direct study.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
High-intensity performance [1]	randomised double-blind placebo-controlled study; trained men	polyphenol-rich extract, 4 weeks	Selected performance markers improved during high-intensity exertion.	Small sports study; the result belongs to the specific extract.
Performance of trained athletes [2]	randomised placebo-controlled study	citrus flavonoid supplement	A slight increase in performance was observed in an exercise test.	Short duration and a specific sports population.

Strength and limits of the evidence

Several smaller RCTs; the effect is specific to the raw material and to sport.

Safety note

Usually well tolerated. With a citrus allergy or medicines carrying a grapefruit warning, the exact botanical origin and composition of the extract must be known.

Scientific sources

[1] Cases J et al. Supplementation with a polyphenol-rich extract, PerfLoad®, improves physical performance during high-intensity exercise. Nutrients. 2017. View source

[2] Overdevest E et al. Citrus flavonoid supplementation improves exercise performance in trained athletes. J Sports Sci Med. 2018. View source

Green tea extract standardised to EGCG

CATECHIN PLANT EXTRACT

source of catechins, including EGCG
antioxidant research context
need to monitor the dose of EGCG and caffeine precisely

At-a-glance card and understandable research summary

Parameter	Item
Name	Green tea extract standardised to EGCG
Category	catechin plant extract
Origin / nature	leaves of Camellia sinensis
Products / formulations	postbiotic block with pasteurised Akkermansia muciniphila Mucᵀ
Main role	separate polyphenol component of the combination

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Green tea contains catechins, the best known of which is EGCG. The extract behaves differently from ordinary tea: it can be much more concentrated, and its safety depends on the daily dose, on taking it on an empty stomach and on individual sensitivity.

EFSA noted that with supplements providing 800 mg EGCG a day or more, increases in liver enzymes were observed in intervention studies [1]. The card should therefore emphasise the EGCG content of the daily dose, not just the amount of extract.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Safety of catechins [1]	systematic EFSA safety assessment	various supplement doses	Green tea infusions were generally safe; with concentrated supplements of ≥800 mg EGCG/day, a signal for liver enzymes appeared.	There is no set safe limit that applies to everyone; the individual dose and context matter.
Clinical safety [2]	randomised placebo-controlled study of a catechin extract	standardised extract	The study looked specifically at safety and confirmed the need to monitor liver adverse effects with concentrated extracts.	A different raw material and dose than in the postbiotic block.

Strength and limits of the evidence

Extensive research on catechins; for a specific block, the exact EGCG and caffeine content per daily dose must be known.

Safety note

Do not take on an empty stomach. In liver disease, raised liver tests, pregnancy or concurrent medicines, consultation is advisable. The daily EGCG content must be clearly stated and assessed under the applicable EU rules.

Scientific sources

[1] EFSA ANS Panel. Scientific opinion on the safety of green tea catechins. EFSA Journal. 2018. View source

[2] Kumar NB et al. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Cancer Prev Res. 2016. View source

Omega-3 fatty acids EPA and DHA from microalgae

LONG-CHAIN POLYUNSATURATED FATTY ACIDS

EPA + DHA and normal function of the heart at 250 mg/day
DHA as a structural component of the nervous system and retina
vegan source without the need for fish oil

At-a-glance card and understandable research summary

Parameter	Item
Name	Omega-3 fatty acids EPA and DHA from microalgae
Category	long-chain polyunsaturated fatty acids
Origin / nature	oil from the microalgae Schizochytrium sp.; triglyceride form according to the product documentation
Products / formulations	iProbio omega‑3; HIT na Trávenie+®
Main role	separate lipid active ingredient; not a prebiotic

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

One iProbio omega‑3 capsule contains 150 mg EPA and 100 mg DHA, 250 mg in total. At this daily dose, and provided the other conditions are met, the authorised EU claim that EPA and DHA contribute to the normal function of the heart can be used [1].

Research on higher doses in specific clinical conditions cannot be transferred to a 250 mg supplement. Large cardiovascular studies often used about 1 g of a blend or 4 g of a prescription EPA form; these are different doses, populations and purposes [2].

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Authorised EU claim [1]	regulatory assessment	250 mg EPA + DHA/day	EPA and DHA contribute to the normal function of the heart.	The claim applies only when the conditions on composition and labelling are met.
Research on omega‑3 after a heart attack [2]	large open-label randomised study; 11 324 patients after a heart attack	about 1 g n‑3 PUFA/day	In the study, the risk of combined major events and of death was reduced.	A treated patient population and a higher dose; the result is not direct evidence for an ordinary supplement.
Memory in older adults [3]	randomised double-blind placebo-controlled study; 485 adults with mild memory decline	900 mg DHA/day, 24 weeks	Selected learning and memory tests improved.	A higher dose of DHA alone; it cannot be transferred to 100 mg of DHA in a capsule.

Strength and limits of the evidence

Strong nutritional support for EPA/DHA, but clinical results are specific to dose and population.

Safety note

With anticoagulants, a bleeding disorder or planned surgery, consultation is advisable, especially at higher doses. The oxidation parameters of the oil and correct storage are important. With an algal source, fish protein allergy does not apply, but the other capsule ingredients should be checked.

Scientific sources

[1] Commission Regulation (EU) No 432/2012 – permitted health claims for EPA and DHA. View source

[2] GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction. Lancet. 1999. View source

[3] Yurko-Mauro K et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010. View source

L-glutamine

AMINO ACID; METABOLIC SUBSTRATE

research on intestinal permeability
research in post-infectious IBS with diarrhoea
metabolic, not prebiotic ingredient

At-a-glance card and understandable research summary

Parameter	Item
Name	L-glutamine
Category	amino acid; metabolic substrate
Origin / nature	free form of the amino acid glutamine
Products / formulations	optional ingredient of personalised formulations according to the working list
Main role	nutrient for rapidly dividing cells; not a prebiotic

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Glutamine is an amino acid used by intestinal and immune cells. In the library we therefore classify it among amino acids, not prebiotics.

One RCT in post-infectious IBS with diarrhoea and increased intestinal permeability recorded an improvement in both symptoms and permeability at a high targeted dose [1]. This result cannot be transferred to a small technological amount in a blend of microorganisms.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Post-infectious IBS-D [1]	randomised double-blind placebo-controlled study; patients with post-infectious IBS-D and increased permeability	5 g three times a day, 8 weeks	The symptom score, stool frequency and measured intestinal permeability all improved.	A selected population and a dose of 15 g/day; the result is not evidence of an effect at lower doses.

Strength and limits of the evidence

Interesting clinical support in a narrowly defined population; it is not a general prebiotic.

Safety note

In severe liver or kidney disease, cancer treatment, pregnancy or at high doses, consult a doctor.

Scientific sources

[1] Zhou Q et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019. View source

N-acetyl-L-cysteine (NAC)

AMINO ACID DERIVATIVE AND PRECURSOR OF CYSTEINE/GLUTATHIONE

glutathione precursor
research on redox balance
separate bioactive substance

At-a-glance card and understandable research summary

Parameter	Item
Name	N-acetyl-L-cysteine (NAC)
Category	amino acid derivative and precursor of cysteine/glutathione
Origin / nature	acetylated form of L-cysteine
Products / formulations	optional ingredient of personalised formulations according to the working list
Main role	antioxidant and mucolytic research context; not a prebiotic

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

NAC supplies the cysteine needed for glutathione formation and also has direct redox properties [1]. In a formulation with microorganisms it cannot be described as food for beneficial bacteria; it is a separate bioactive substance.

NAC is also a medicinal substance used in specific indications. For a food supplement, the nutritional context must therefore be clearly distinguished from therapeutic claims, and the national regulatory status of the dose verified.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Mechanism and clinical use [1]	expert pharmacological review	various medicine and supplement regimens	NAC serves as a source of cysteine for glutathione and affects oxidation-reduction processes.	The review is not evidence of the effect of a specific blend of microorganisms.

Strength and limits of the evidence

Well-known pharmacology; strain- or product-specific synergistic efficacy has not been demonstrated.

Safety note

May cause nausea or digestive discomfort. Caution with nitroglycerin, clotting disorders, asthma and before surgery. The dose should also be assessed from a regulatory point of view.

Scientific sources

[1] Pedre B et al. The mechanism of action of N-acetylcysteine (NAC): the emerging role of H2S and sulfane sulfur species. Pharmacol Ther. 2021. View source

L-lysine

ESSENTIAL AMINO ACID

protein-building amino acid
nutritional ingredient
do not adopt antiviral claims without direct evidence

At-a-glance card and understandable research summary

Parameter	Item
Name	L-lysine
Category	essential amino acid
Origin / nature	free form of L-lysine or its salt according to the specification
Products / formulations	HIT na Trávenie+®
Main role	amino acid component; not a prebiotic

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

L-lysine is an essential amino acid that humans must obtain from their diet. In HIT na Trávenie+®, it is a supplementary amino acid component, not a prebiotic.

Although lysine is often promoted in connection with cold sores, a systematic review found no convincing evidence for the prevention of herpes labialis [1]. For customer communication it is therefore advisable to stay with its nutritional identity and not state an antiviral benefit.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Research on lysine in recurrent cold sores [1]	systematic review of interventions	various lysine regimens	No reliable preventive efficacy of lysine was confirmed.	A negative or inconclusive result is a reason not to use an antiviral claim.

Strength and limits of the evidence

A clear nutritional role; specific health claims for lysine on its own are limited.

Safety note

Usual doses are generally well tolerated; higher doses may cause digestive problems. In kidney disease, consult a doctor.

Scientific sources

[1] Chi CC et al. Interventions for prevention of herpes simplex labialis (cold sores on the lips). Cochrane Database Syst Rev. 2015. View source

Zinc L-methionine

ORGANIC FORM OF THE MINERAL ZINC BOUND TO AN AMINO ACID

source of zinc
normal function of the immune system when the conditions of the claim are met
protection of cells from oxidative stress when the conditions of the claim are met

At-a-glance card and understandable research summary

Parameter	Item
Name	Zinc L-methionine
Category	organic form of the mineral zinc bound to an amino acid
Origin / nature	complex of zinc with L-methionine according to the raw material specification
Products / formulations	optional ingredient of personalised formulations according to the working list
Main role	source of zinc; not a prebiotic

How to read the card: The areas listed describe research on the ingredient or its technological role. They do not mean a therapeutic indication or a guaranteed result.

Information about the ingredient

Zinc L-methionine is a mineral-amino acid complex. Its purpose is to supply zinc in a defined form; it is not a prebiotic and it cannot be claimed that it selectively feeds gut bacteria.

For zinc there are authorised EU claims, including a contribution to the normal function of the immune system and the protection of cells from oxidative stress [1]. They may be used only if the product’s daily dose meets the “source of zinc” condition.

Detailed expert profile

Overview of scientific studies

Area studied	Design and population	Dose / duration	Observation in the published study	How to read the result
Authorised functions of zinc [1]	EU regulatory assessment	according to the conditions of use of the claim	Zinc has several authorised physiological claims.	The claims belong to the nutrient zinc, not to a specific binding to methionine or to the whole blend.

Strength and limits of the evidence

Strong nutritional support for zinc; the advantage of the specific chelated form must be demonstrated separately.

Safety note

Long-term high zinc intake can interfere with copper metabolism. Take all sources of zinc and the tolerable upper intake level into account.

Scientific sources

[1] Commission Regulation (EU) No 432/2012 – permitted health claims for zinc. View source

SUMMARY CHAPTER

Vitamins and minerals

This chapter lists the nutritional functions that have authorised health claims in the EU. On the website they may be used only if the specific product meets the “source of” condition or another condition set out in the regulation. A trace technological amount is not enough [1].

Substance	Where it is found	Authorised physiological context – in brief
Thiamine (B1)	CARDIObiom+®, SPORTbiom+®	energy-yielding metabolism, nervous system and normal function of the heart
Riboflavin (B2)	VITALbiom+®; section on A. muciniphila Mucᵀ	energy-yielding metabolism, mucous membranes, red blood cells and protection of cells from oxidative stress
Niacin (B3)	LADYbiom+®	energy-yielding metabolism, nervous system, psychological function, skin and mucous membranes
Vitamin B6	SPORTbiom+®	energy and protein metabolism, nervous and immune systems
Biotin (B7)	LADYbiom+®, SPORTbiom+®	macronutrient metabolism, nervous system, skin, hair and mucous membranes
Vitamin B12	SPORTbiom+®	energy-yielding metabolism, nervous and immune systems, blood formation and cell division
Vitamin D3	CARDIObiom+®, iMunobiom+®, VITALbiom+®, section on A. muciniphila Mucᵀ	immune system, muscles, bones and the utilisation of calcium
Magnesium	SPORTbiom+®	energy-yielding metabolism, nervous system, muscle function, electrolyte balance and reduction of tiredness and fatigue
Potassium	carrier blends of personalised blocks in the form of KCl	nervous system, muscles and maintenance of normal blood pressure – only at a nutritionally relevant dose
Manganese	carrier blends of personalised blocks in the form of MnSO₄	energy-yielding metabolism, bones, connective tissue and protection of cells from oxidative stress – only at a relevant dose
Chromium	block with A. muciniphila Mucᵀ	macronutrient metabolism and maintenance of normal blood glucose levels

Watch the form: Magnesium sulphate, manganese sulphate and potassium chloride in a carrier matrix may not provide a nutritionally relevant dose of the mineral. A nutrition claim can be assigned only to the finished product with a verified amount of the nutrient.

Scientific sources

[1] Commission Regulation (EU) No 432/2012 establishing a list of permitted health claims made on foods – consolidated version. View source

[2] EFSA. Health claims – how claims are scientifically assessed and authorised. View source

SUMMARY CHAPTER

Technological and carrier substances

These substances serve primarily a manufacturing function: they improve flowability, stability, dosing, protection during drying or capsule formation. Their presence matters for product quality, but should not be confused with the clinical effect of the active ingredient.

Substance	Function in the formulation	What exactly to communicate
Maltodextrin	carrier, bulking agent, protective matrix during drying	Not automatically a prebiotic. Resistant maltodextrin is a different, specifically modified fibre.
Maize starch	bulking agent/carrier	Ordinary digestible starch should not be labelled a prebiotic. Resistant maize starch is a different raw material.
Potato starch	bulking agent/carrier in Bio‑Three, Butyrate generator and Gut enricher	Prebiotic properties may be stated only where the resistant starch content is confirmed.
Hydrolysed rice protein	source of peptides for the manufacturing/stabilising matrix	Not an established prebiotic; in rice allergy, check for residual proteins.
Lactose	carrier and fermentable carbohydrate	Not a general prebiotic. Important warning for lactose intolerance; allergen status depends on milk protein residues and labelling.
Potassium chloride	mineral salt in the carrier blend	At a technological dose it should not be presented as a source of potassium. Caution in hyperkalaemia and with medicines that raise potassium.
Magnesium sulphate	mineral salt supporting the manufacturing culture/stabilising matrix	Not to be confused with the declared nutritional dose of magnesium in the finished product.
Manganese sulphate	trace mineral salt in a technological matrix	Not to be confused with supplementation of manganese at a nutritionally relevant level.
Povidone (PVP)	binder, stabiliser and excipient	The effect of live microorganisms or of a selective substrate for the gut microbiome should not be attributed to it.
Fully hydrolysed polyvinyl alcohol (PVA)	protective/film-forming technological ingredient	Use and purity should follow the specification; this is not a bioactive ingredient.
Microcrystalline cellulose	bulking agent and binder	At an ordinary technological amount it should not be presented as a prebiotic.
Magnesium stearate	lubricant and anti-caking excipient	The correct name is stearate, not “stereate”. It is not a magnesium source of nutritional significance.
Silicon dioxide (E551)	anti-caking agent	Improves the flowability of the powder; it is neither a prebiotic nor an active ingredient.
Hydroxypropyl methylcellulose – HPMC (E464)	plant-based capsule shell, thickener	Technological function; do not present as an active fibre.
Hydroxypropyl cellulose – HPC (E463)	binder/film-forming agent	Technological component of the postbiotic block.
Gellan gum (E418)	gelling and stabilising agent	Technological function; the amount is usually lower than a fibre dose.
Mono- and diglycerides of fatty acids (E471)	emulsifier	Technological function; no nutritional effect of omega‑3 can be inferred from the name.
Calcium phosphates (E341)	anti-caking agent/bulking agent	At a technological dose they should not automatically be communicated as a source of calcium.

The label takes precedence: Before publishing, the name, E number, amount, allergen status and technological function should be compared with the current specification and the label of the finished product.

Scientific sources

[1] Regulation (EC) No 1333/2008 on food additives – consolidated text. View source

[2] Regulation (EU) No 1169/2011 on the provision of food information to consumers. View source

General notice: This document is an expert and educational resource. It does not replace healthcare or an individual assessment of medicines, diagnoses, allergies, pregnancy or severe immunodeficiency. The final web version should undergo a regulatory check according to the context of sale.

Strains for personalised formulations

The separate iProbio 2.0® line is based on microbiome analysis and expert assessment. This library presents the microorganisms and complexes used in putting together individual formulations.

Purpose of the document: The document combines a clear card, an understandable summary of biological properties and research directions, and a detailed scientific profile. For each item, one numbering of sources applies across all three layers.

How to read the library

How the library is organised

Layer 1 – name, taxonomic or compositional table and brief points on the areas studied in research.

Layer 2 – a readable educational summary of biological properties and research directions, which preserves citations, inconsistent results and the difference between clinical and preclinical data.

Layer 3 – detailed scientific context, annotations of key studies, role in complexes, safety and the full list of sources.

Regulatory note: Neither length nor citation alone makes a text suitable for a commercial B2C page. Sections containing diagnoses and specific effects must undergo legal review before publication, according to the overall context of the page [R1–R3].

Regulatory sources

[R1] Regulation (EC) No 1924/2006 on nutrition and health claims made on foods. View source

[R2] Regulation (EU) No 1169/2011 on the provision of food information to consumers, in particular Article 7. View source

[R3] European Commission: EU Register of Nutrition and Health Claims. View source